"","pmid","doi","title","abstract","year","month","day","jabbrv","journal","keywords","lastname","firstname","address","email"
"1","32474009","10.1016/j.cca.2020.05.044","COVID-19: Transmission, prevention, and potential therapeutic opportunities.","The novel coronavirus disease (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), remains a global challenge. Despite intense research efforts worldwide, an effective vaccine and viable treatment options have eluded investigators. Therefore, infection prevention, early viral detection and identification of successful treatment protocols provide the best approach in controlling disease spread. In this review, current therapeutic options, preventive methods","2020","07","22","Clin Chim Acta","Clinica chimica acta; international journal of clinical chemistry","COVID-19; Prevention; SARS-CoV-2; Transmission; Treatment; Adrenal Cortex Hormones; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Repositioning; Humans; Immunization, Passive; Immunologic Factors; Molecular Targeted Therapy; Pandemics; Personal Protective Equipment; Physical Distancing; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Lotfi","Melika","School of Medicine, Zanjan University of Medical Sciences, Zanjan, Iran",NA
"2","32469280","10.1089/hum.2020.29125.lhv","COVID-19: Gene Transfer to the Rescue?",NA,"2020","06","25","Hum Gene Ther","Human gene therapy","Animals; Antibodies, Neutralizing; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Gene Transfer Techniques; Humans; Technology Transfer; Translational Medical Research; Viral Vaccines","Vandenberghe","Luk H","Department of Ophthalmology, Harvard Medical School, Boston, Massachusetts, USA",NA
"3","32466458","10.3390/v12060582","Challenges in Laboratory Diagnosis of the Novel Coronavirus SARS-CoV-2.","The recent outbreak of the Coronavirus disease 2019 (COVID-19) has quickly spread worldwide since its discovery in Wuhan city, China in December 2019. A comprehensive strategy, including surveillance, diagnostics, research, clinical treatment, and development of vaccines, is urgently needed to win the battle against COVID-19. The past three unprecedented outbreaks of emerging human coronavirus infections at the beginning of the 21st century have highlighted the importance of readily available, a","2020","06","02","Viruses","Viruses","COVID-19; SARS-CoV-2; diagnostic challenges; molecular testing; serology; viruses; Asymptomatic Infections; Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Coronavirus Infections; Humans; Immunoenzyme Techniques; Neutralization Tests; Nucleic Acid Amplification Techniques; Pandemics; Pneumonia, Viral; Point-of-Care Testing; Reagent Kits, Diagnostic; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; SARS-CoV-2; Sensitivity and Specificity; Serologic Tests; Tomography, X-Ray Computed; Virus Shedding","Younes","Nadin","Biomedical Research Center, Qatar University, P.O. Box 2713 Doha, Qatar",NA
"4","32466392","10.3390/ijerph17113751","Model for Taking Care of Patients with Early Childhood Caries during the SARS-Cov-2 Pandemic.","Pending the availability of vaccines to contain the SARS-CoV-2 pandemic, the current solution is &quot;social distancing&quot; with a reduction of dental treatments to those assessed as urgent and emergency cases. These treatments also involve Early Childhood Caries (ECC) due to the fact that this disease affects preschool children (a vulnerable population) and, in addition, shows a propensity to evolve into more serious complications (dental pain, infections). A narrative review was carried out","2020","06","17","Int J Environ Res Public Health","International journal of environmental research and public health","SARS-CoV-2; early childhood caries; infection control; minimally invasive; Betacoronavirus; COVID-19; Child; Child, Preschool; Clinical Protocols; Coronavirus Infections; Dental Caries; Humans; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Systematic Reviews as Topic; Tooth, Deciduous","Cianetti","Stefano","Biomedical Sciences, Unit of Paediatric Dentistry, University of Perugia, 06100 Perugia, Italy",NA
"5","32461245","10.1136/medethics-2020-106322","Ethical guidelines for deliberately infecting volunteers with COVID-19.","Global fatalities related to COVID-19 are expected to be high in 2020-2021. Developing and delivering a vaccine may be the most likely way to end the pandemic. If it were possible to shorten this development time by weeks or months, this may have a significant effect on reducing deaths. Phase II and phase III trials could take less long to conduct if they used human challenge methods-that is, deliberately infecting participants with COVID-19 following inoculation. This article analyses arguments","2020","08","18","J Med Ethics","Journal of medical ethics","ethics committees/consultation; informed consent; policy guidelines/Inst; public policy; research ethics; review boards/review Cttes; Betacoronavirus; Biomedical Research; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Ethical Analysis; Ethical Review; Ethics Committees, Research; Ethics, Research; Guidelines as Topic; Human Experimentation; Humans; Informed Consent; Intention; Pandemics; Pneumonia, Viral; Research Design; Research Personnel; Research Subjects; SARS-CoV-2; Vaccination; Viral Vaccines; Volunteers","Richards","Adair D","Department of Chemistry, University of Warwick, Coventry CV4 7AL, UK Adair.Richards@warwick.ac","Adair.Richards@warwick.ac.uk"
"6","32460358","10.1111/imm.13222","The early landscape of coronavirus disease 2019 vaccine development in the UK and rest of the world.","Since the first World Health Organization notification on 31 December 2019, coronavirus disease 2019 (COVID-19), the respiratory disease caused by the coronavirus severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), has been responsible for over four million confirmed infections and almost 300..000 deaths worldwide. The pandemic has led to over half of the world's population living under lockdown conditions. To allow normal life to resume, public health interventions will be needed to p","2020","07","13","Immunology","Immunology","coronavirus disease 2019; severe acute respiratory syndrome coronavirus-2; vaccine; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Protein Subunits; United Kingdom; Vaccines, Attenuated; Vaccines, DNA; Vaccines, Synthetic; Viral Vaccines","Sharpe","Hannah R","The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK",NA
"7","32459832","10.1093/cid/ciaa656","Importance of Pediatric Inclusion in COVID-19 Therapeutic Trials.","Pediatric patients are excluded from most coronavirus disease 2019 (COVID-19) therapeutic trials. We outline a rationale for the inclusion of children in COVID-19 therapeutic trials, which enabled us to include children of all ages in a therapeutic COVID-19 trial at our institution.","2021","01","27","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; SARS-CoV-2; clinical trial; ethics; pediatrics; Adolescent; COVID-19; Child; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunization, Passive; SARS-CoV-2; United States","Raabe","Vanessa N","Department of Pediatrics, Division of Pediatric Infectious Diseases, New York University Grossman School of Medicine, New York, New York, USA",NA
"8","32459574","10.1080/19932820.2020.1770518","The world is waiting, use sequential analysis and get us the evidence-based treatment we need for COVID-19.","In spite of the relatively high morbidity and mortality, there is no approved medication yet for COVID-19. There are more than 200 ongoing trials on different drugs or vaccines, but new medications may take until 2021 to develop. Defining the optimal number of patients to be included in a study is a considerable challenge in these interventional researches. Ethical considerations prompt researchers to minimize the number of patients included in a trial. This gains particular importance when the ","2020","06","08","Libyan J Med","The Libyan journal of medicine","COVID-19; Sequential analysis; clinical trials; treatment; Antiviral Agents; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Drug Discovery; Evidence-Based Medicine; Global Health; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","El Taguri","Adel","National Center for Accreditation of Health Establishments- , Tripoli-Libya, Libya",NA
"9","32456404","10.23736/S0031-0808.20.03958-0","The vaccine journey for COVID-19: a comprehensive systematic review of current clinical trials in humans.","Since December 2019, there has been an outbreak of a novel beta-coronavirus (SARS-CoV-2) in Wuhan, China. On March the 11th the World Health Organization (WHO) declared COVID-19 as a pandemic, with over 118,000 cases in more than 110 countries around the world. In response to the global coronavirus disease 2019 (COVID-19) emergency, clinical trial research assessing the efficacy and safety of experimental vaccines to prevent COVID-19 are emerging at an unprecedented rate. The aim of this systema","2020","05","27","Panminerva Med","Panminerva medica",NA,"Checcucci","Enrico","Department of Oncology, School of Medicine, San Luigi Hospital, University of Turin, Orbassano, Turin, Italy - checcu.e@hotmail","checcu.e@hotmail.it"
"10","32453605","10.4155/bio-2020-0116","Rapid and robust bioanalytical assays are critical for SARS-CoV-2 therapeutic and vaccine development and beyond.",NA,"2020","10","08","Bioanalysis","Bioanalysis","COVID-19; neutralizing antibodies; serology; viral load; Antiviral Agents; Betacoronavirus; Biomarkers; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Load; Viral Vaccines","Kar","Sumit","Bioanalytical Sciences, Celerion Inc. 621 Rose St, Lincoln, NE 68502, USA",NA
"11","32452350","","Understanding immune effects of oestrogens to explain the reduced morbidity and mortality in female versus male COVID-19 patients. Comparisons with autoimmunity and vaccination.",NA,"2020","06","04","Clin Exp Rheumatol","Clinical and experimental rheumatology","Autoimmunity; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Estrogens; Female; Humans; Male; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sex Factors; Vaccination; Viral Vaccines","Cutolo","Maurizio","Research Laboratory and Academic Division of Clinical Rheumatology, Department of Internal Medicine DiMI, University of Genova, IRCCS San Martino Polyclinic, Genova, Italy. mcutolo@unige","mcutolo@unige.it"
"12","32450106","10.1016/S0140-6736(20)31208-3","Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.","A vaccine to protect against COVID-19 is urgently needed. We aimed to assess the safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 (Ad5) vectored COVID-19 vaccine expressing the spike glycoprotein of a severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) strain. We did a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. Healthy adults aged between 18 and 60 years were sequentially enrol","2020","06","17","Lancet","Lancet (London, England)","Adenoviridae; Adolescent; Adult; Antibodies, Neutralizing; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Coronavirus Infections; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunity, Cellular; Immunity, Humoral; Injections, Intramuscular; Male; Middle Aged; Pandemics; Pneumonia, Viral; SARS-CoV-2; T-Lymphocytes; Vaccines, Synthetic; Viral Vaccines; Young Adult","Zhu","Feng-Cai","NHC Key Laboratory of Enteric Pathogenic Microbiology, Jiangsu Provincial Center for Disease Control and Prevention, Nanjing, China. Electronic address: jszfc@vip.sina","jszfc@vip.sina.com"
"13","32444382","10.1128/mBio.01114-20","Antiviral Efficacies of FDA-Approved Drugs against SARS-CoV-2 Infection in Ferrets.","Due to the urgent need of a therapeutic treatment for coronavirus (CoV) disease 2019 (COVID-19) patients, a number of FDA-approved/repurposed drugs have been suggested as antiviral candidates at clinics, without sufficient information. Furthermore, there have been extensive debates over antiviral candidates for their effectiveness and safety against severe acute respiratory syndrome CoV 2 (SARS-CoV-2), suggesting that rapid preclinical animal studies are required to identify potential antiviral ","2020","06","03","mBio","mBio","COVID-19; antiviral therapeutics; ferrets; immunosuppression; serum neutralization; severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2); Animals; Antibodies, Neutralizing; Antibodies, Viral; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Disease Models, Animal; Female; Ferrets; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; United States; United States Food and Drug Administration; Viral Load","Park","Su-Jin","Department of Microbiology, Chungbuk National University College of Medicine and Medical Research Institute, Cheongju, Republic of Korea",NA
"14","32442040","10.1080/14740338.2020.1773789","SARS-CoV-2, from its current highly contagious spreading toward the global development of an effective and safe vaccine: challenges and uncertainties.",NA,"2020","08","10","Expert Opin Drug Saf","Expert opinion on drug safety","Coronavirus; clinical development; vaccine; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Drug Resistance, Viral; Humans; Immunity; Pandemics; Patient Safety; Pneumonia, Viral; Risk Adjustment; SARS-CoV-2; Therapeutic Index; Viral Vaccines","Merante","Domenico","Global Clinical Development , Amersham, UK",NA
"15","32441894","10.1002/eahr.500056","Why Challenge Trials of SARS-CoV-2 Vaccines Could Be Ethical Despite Risk of Severe Adverse Events.","Human challenge trials to test the efficacy of vaccine candidates against SARS-CoV-2, the novel coronavirus behind Covid-19, could save considerable time and many lives. But they may initially seem unethical because they expose healthy volunteers to a live virus that is killing many people and for which no cure exists. This article argues that this is not the correct test of their ethics. The correct test is comparative. And in the special circumstances of the Covid-19 pandemic, human challenge ","2020","07","27","Ethics Hum Res","Ethics &amp; human research","Covid-19; coronavirus; human challenge studies; randomized controlled trials; research ethics; risk taking; vaccines; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2; Viral Vaccines","Eyal","Nir","Directs the Center for Population-Level Bioethics at Rutgers University and is the Henry Rutgers professor of bioethics in the Department of Health Behavior, Society and Policy at Rutgers School of Public Health and in the Department of Philosophy at Rutgers's School of Arts and Sciences",NA
"16","32439768","10.1126/science.368.6493.807","Long-acting drug acts like a short-term AIDS vaccine.",NA,"2020","06","11","Science","Science (New York, N.Y.)","AIDS Vaccines; Acquired Immunodeficiency Syndrome; Anti-HIV Agents; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Delayed-Action Preparations; Emtricitabine, Tenofovir Disoproxil Fumarate Drug Combination; Humans; Injections, Intramuscular; Pandemics; Pneumonia, Viral; Pyridones; Time Factors","Cohen","Jon",NA,NA
"17","32437659","10.1016/j.cell.2020.04.042","Trained Immunity: a Tool for Reducing Susceptibility to and the Severity of SARS-CoV-2 Infection.","SARS-CoV-2 infection is mild in the majority of individuals but progresses into severe pneumonia in a small proportion of patients. The increased susceptibility to severe disease in the elderly and individuals with co-morbidities argues for an initial defect in anti-viral host defense mechanisms. Long-term boosting of innate immune responses, also termed &quot;trained immunity,&quot; by certain live vaccines (BCG, oral polio vaccine, measles) induces heterologous protection against infections th","2020","06","05","Cell","Cell","Animals; BCG Vaccine; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunity, Innate; Immunomodulation; Lung; Lymphopenia; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Virus Replication","Netea","Mihai G","Department of Internal Medicine and Center for Infectious Diseases, Radboud University, 6500 Nijmegen, the Netherlands","mihai.netea@radboudumc.nl"
"18","32437587","10.1002/eji.202048663","COVID-19 vaccines: Knowing the unknown.","Vaccine development against SARS-CoV-2 has drawn attention around the globe due to the exploding pandemic. Although COVID-19 is caused by a new coronavirus, SARS-CoV-2, previous research on other coronavirus vaccines, such as FIPV, SARS, and MERS, has provided valuable information for the rapid development of COVID-19 vaccine. However, important knowledge gaps remain - some are specific to SARS-CoV-2, others are fundamental to immunology and vaccinology. Here, we discuss areas that need to be ad","2020","07","08","Eur J Immunol","European journal of immunology","COVID-19; SARS-CoV-2; Vaccine; Animals; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Lv","Huibin","HKU-Pasteur Research Pole, School of Public Health, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong SAR, China",NA
"19","32434788","10.1136/jitc-2020-000892","COVID-19 and lung cancer: risks, mechanisms and treatment interactions.","Cases of the 2019 novel coronavirus also known as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continue to rise worldwide. To date, there is no effective treatment. Clinical management is largely symptomatic, with organ support in intensive care for critically ill patients. The first phase I trial to test the efficacy of a vaccine has recently begun, but in the meantime there is an urgent need to decrease the morbidity and mortality of severe cases. It is known that patients with","2020","05","29","J Immunother Cancer","Journal for immunotherapy of cancer","T-Lymphocytes; immunity; lung neoplasms; Antibodies, Monoclonal, Humanized; Antiviral Agents; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Hydroxychloroquine; Interleukin-6; Lung; Lung Neoplasms; Neoplasms; Pandemics; Pneumonia, Viral; Risk Factors; SARS-CoV-2","Addeo","Alfredo","Oncology, University Hospitals Geneva, Geneve, Switzerland alfredo.addeo@hcuge","alfredo.addeo@hcuge.ch"
"20","32425691","10.1016/j.jcyt.2020.05.002","International Society for Extracellular Vesicles and International Society for Cell and Gene Therapy statement on extracellular vesicles from mesenchymal stromal cells and other cells: considerations for potential therapeutic agents to suppress coronavirus disease-19.","The International Society for Cellular and Gene Therapies (ISCT) and the International Society for Extracellular Vesicles (ISEV) recognize the potential of extracellular vesicles (EVs, including exosomes) from mesenchymal stromal cells (MSCs) and possibly other cell sources as treatments for COVID-19. Research and trials in this area are encouraged. However, ISEV and ISCT do not currently endorse the use of EVs or exosomes for any purpose in COVID-19, including but not limited to reducing cytoki","2020","09","07","Cytotherapy","Cytotherapy","COVID-19; Coronavirus Infections; Exosomes; Extracellular Vesicles; Humans; Mesenchymal Stem Cells; Societies, Scientific","B..rger","Verena","Institute for Transfusion Medicine, University Hospital Essen, University of Duisburg-Essen, Essen, Germany",NA
"21","32425638","10.1016/j.ijid.2020.05.040","Reducing mortality and morbidity in patients with severe COVID-19 disease by advancing ongoing trials of Mesenchymal Stromal (stem) Cell (MSC) therapy - Achieving global consensus and visibility for cellular host-directed therapies.","As of May 17th 2020, the novel coronavirus disease 2019 (COVID-19) pandemic has caused 307,395 deaths worldwide, out of 3,917,366 cases reported to the World Health Organization. No specific treatments for reducing mortality or morbidity are yet available. Deaths from COVID-19 will continue to rise globally until effective and appropriate treatments and/or vaccines are found. In search of effective treatments, the global medical, scientific, pharma and funding communities have rapidly initiated ","2020","07","28","Int J Infect Dis","International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases","Betacoronavirus; COVID-19; Clinical Trials as Topic; Consensus; Coronavirus Infections; Humans; Mesenchymal Stem Cell Transplantation; Morbidity; Pandemics; Pneumonia, Viral; SARS-CoV-2","Zumla","Alimuddin","Department of Infection, Division of Infection and Immunity, University College London, and National Institutes of Health and Research Biomedical Research Centre, University College London Hospitals NHS Foundation Trust, London, United Kingdom. Electronic address: a.zumla@ucl.ac","a.zumla@ucl.ac.uk"
"22","32425416","10.1016/j.jor.2020.05.010","The role of an Orthopaedic Surgeon in the time of Covid-19 Pandemic-a German perspective.","Covid-19 is a non-orthopaedic disease but is affecting the community of Orthopaedics as much as every part of our daily living. In this Editorial the different aspects of changes in our routine are described, based on the experience of this Editor in Germany. I will try to give you a bit of background information first, as the situation is very much dependent on the specific phase of the pandemic and your place of work. The experience for an Orthopaedic Surgeon in New York or Madrid may differ f","2021","01","19","J Orthop","Journal of orthopaedics",NA,"Graichen","Heiko","Department for Arthroplasty, Orthopaedic Hospital Asklepios Lindenlohe, Lindenlohe 18, 92421 Schwandorf, Germany",NA
"23","32423342","10.1080/10837450.2020.1764670","COVID-19 pandemic: what can pharmaceutical formulation and drug delivery experts offer?",NA,"2020","05","21","Pharm Dev Technol","Pharmaceutical development and technology","Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Repositioning; Drugs, Investigational; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Alany","Raid G","Professor of Pharmaceutical Formulation and Drug Delivery, Kingston University London, Kingston upon Thames, UK",NA
"24","32420637","10.1002/ddr.21689","Repurposing current therapeutics for treating COVID-19: A vital role of prescription records data mining.","Since its outbreak in late 2019, the SARS-Cov-2 pandemic already infected over 3.7 million people and claimed more than 250,000 lives globally. At least 1...year may take for an approved vaccine to be in place, and meanwhile millions more could be infected, some with fatal outcome. Over thousand clinical trials with COVID-19 patients are already listed in ClinicalTrials.com, some of them for assessing the utility of therapeutics approved for other conditions. However, clinical trials take many m","2020","12","04","Drug Dev Res","Drug development research","COVID-19; TMPRSS2; drug repositioning; drug repurposing; electronic health records (EHR); Antiviral Agents; COVID-19; Clinical Trials as Topic; Data Mining; Drug Repositioning; Electronic Health Records; Humans; Retrospective Studies; SARS-CoV-2; Time Factors","Gurwitz","David","Department of Human Molecular Genetics and Biochemistry, Sackler Faculty of Medicine, Tel Aviv, Israel",NA
"25","32417996","10.1007/s00345-020-03251-7","BCG versus COVID-19: impact on urology.","To search for evidence base for using BCG in the fight against COVID-19 and the possible impact of these clinical trials on urology practice. A literature review about the basis of the ongoing clinical trials using BCG against COVID-19, as well as the use of BCG in urology and if there are any implications of these trials on our practice. Based on data from some epidemiological studies, there are some current clinical trials on the use BCG as a possible prophylactic vaccine against SARS CoV-2 wh","2021","03","25","World J Urol","World journal of urology","BCG; Bladder cancer; COVID-19; Pandemic; Urology; Adjuvants, Immunologic; Administration, Intravesical; BCG Vaccine; COVID-19; Carcinoma, Transitional Cell; Clinical Trials as Topic; Humans; SARS-CoV-2; Urinary Bladder Neoplasms; Urology","Desouky","Elsayed","Urology Department, Wexham Park NHS Hospital, Berkshire, UK. sayedurology@hotmail","sayedurology@hotmail.com"
"26","32417802","10.3233/NPM-200460","The changing landscape of SARS-CoV-2: Implications for the maternal-infant dyad.","The COVID-19 pandemic represents the greatest challenge to date faced by the medical community in the 21st century. The rate of rapid dissemination, magnitude of viral contagiousness, person to person transmission at an asymptomatic phase of illness pose a unique and dangerous challenge for all patients, including neonatal and obstetric patients. Although scientific understanding of the pathophysiology of the disease, nature of transmission, and efficacy of mitigation strategies is growing, neit","2020","09","22","J Neonatal Perinatal Med","Journal of neonatal-perinatal medicine","SARS-CoV-2; angiotensin-converting enzyme 2 (ACE2); pandemic; pneumonia; Betacoronavirus; COVID-19; Coronavirus Infections; Female; Humans; Infant, Newborn; Infectious Disease Transmission, Vertical; Pandemics; Perinatal Care; Pneumonia, Viral; Pregnancy; Pregnancy Complications, Infectious; SARS-CoV-2","Elgin","T G","Stead Family Children's Hospital Department of Pediatrics, Neonatology Division, University of Iowa, Iowa City, IA, USA",NA
"27","32414757","10.1136/medethics-2020-106235","Ethical considerations for epidemic vaccine trials.","Vaccines are a powerful measure to protect the health of individuals and to combat outbreaks such as the COVID-19 pandemic. An ethical dilemma arises when one effective vaccine has been successfully developed against an epidemic disease and researchers seek to test the efficacy of another vaccine for the same pathogen in clinical trials involving human subjects. On the one hand, there are compelling reasons why it would be unethical to trial a novel vaccine when an effective product exists alrea","2020","07","16","J Med Ethics","Journal of medical ethics","clinical trials; ethics; Betacoronavirus; Bioethical Issues; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Health Care Rationing; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Monrad","Joshua Teperowski","Program in Ethics, Politics, and Economics, Yale University, New Haven, CT, USA joshua.monrad@yale","joshua.monrad@yale.edu"
"28","32412556","10.1016/j.chaos.2020.109888","Characterization of the COVID-19 pandemic and the impact of uncertainties, mitigation strategies, and underreporting of cases in South Korea, Italy, and Brazil.","By April 7th, 2020, the Coronavirus disease 2019 (COVID-19) has infected one and a half million people worldwide, accounting for over 80 thousand of deaths in 209 countries and territories around the world. The new and fast dynamics of the pandemic are challenging the health systems of different countries. In the absence of vaccines or effective treatments, mitigation policies, such as social isolation and lock-down of cities, have been adopted, but the results vary among different countries. So","2021","01","10","Chaos Solitons Fractals","Chaos, solitons, and fractals","COVID-19; Epidemiology; Mathematical modeling; Sensitivity analysis; Uncertainty quantification","Reis","Ruy Freitas","Departamento de Ci..ncia da Computa....o, Universidade Federal de Juiz de Fora, Brazil",NA
"29","32410772","10.1016/j.biopha.2020.110267","Emerging pharmacotherapies for COVID-19.","Novel Corona-virus Disease 2019 (nCOVID 19) is caused by a novel virulent corona virus and leads to potentially fatal virulent pneumonia and severe respiratory distress syndrome. It was initially declared as public health emergency if international concern by WHO followed by Pandemic on 12th March 2020. As of 10th April 2020, more than 1.5 million people are affected globally with around 95,000 deaths. Vaccines for this deadly virus are currently under development and many drugs used for other i","2020","06","30","Biomed Pharmacother","Biomedicine &amp; pharmacotherapy = Biomedecine &amp; pharmacotherapie","Chloroquine; Hydroxychloroquine; Remdesivir; Anti-Inflammatory Agents; Antimalarials; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Cytokine Release Syndrome; Drug Discovery; Drug Repositioning; Humans; Immunologic Factors; Pandemics; Pneumonia, Viral; SARS-CoV-2","Salvi","Rachana","Department of Pharmacology &amp",NA
"30","32410758","10.1016/S0140-6736(20)31029-1","Consider pregnancy in COVID-19 therapeutic drug and vaccine trials.",NA,"2020","05","29","Lancet","Lancet (London, England)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Female; Humans; Pandemics; Patient Selection; Pneumonia, Viral; Pregnancy; Pregnant Women; SARS-CoV-2; Viral Vaccines","Whitehead","Clare L","Department of Obstetrics and Gynaecology, University of Melbourne, Parkville, VIC 3052, Australia","clarew@unimelb.edu.au"
"31","32409451","10.1126/science.368.6492.692","U.S. 'Warp Speed' vaccine effort comes out of the shadows.",NA,"2020","06","11","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Mass Vaccination; Pandemics; Pneumonia, Viral; United States; Viral Vaccines","Cohen","Jon",NA,NA
"32","32407706","10.1016/j.chom.2020.04.019","SARS-CoV-2: A New Song Recalls an Old Melody.","The viruses causing the SARS outbreak of 2002-2003 and current COVID-19 pandemic are related betacoronaviruses. What insights were learned from SARS that can inform SARS-CoV-2 vaccine development? Focusing on important lessons from SARS vaccine development and two SARS vaccines evaluated in humans may guide SARS-CoV-2 vaccine design, testing, and implementation.","2020","05","18","Cell Host Microbe","Cell host &amp; microbe","Animals; Antibodies, Neutralizing; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Spike Glycoprotein, Coronavirus; Viral Vaccines","Subbarao","Kanta","WHO Collaborating Centre for Reference and Research on Influenza and Department of Microbiology and Immunology, University of Melbourne at The Peter Doherty Institute for Infection and Immunity, 792 Elizabeth Street, Melbourne, VIC 3000, Australia. Electronic address: kanta.subbarao@influenzacenter","kanta.subbarao@influenzacenter.org"
"33","32407539","10.1002/cpt.1891","Clinical Trials for COVID-19: Can we Better Use the Short Window of Opportunity?","The scientific community has risen to the coronavirus disease 2019 (COVID-19) challenge, coming up with an impressive list of candidate drugs and vaccines targeting an array of pharmacological and immunological mechanisms. Yet, generating clinical evidence of efficacy and safety of these candidate treatments may be frustrated by the absence of comprehensive trial coordination mechanisms. Many small stand-alone trials and observational studies of single-agent interventions are currently running o","2020","09","29","Clin Pharmacol Ther","Clinical pharmacology and therapeutics","Academic Medical Centers; Betacoronavirus; Biomedical Research; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Drug Industry; Drug and Narcotic Control; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Time Factors","Eichler","Hans-Georg","European Medicines Agency (EMA), Amsterdam, The Netherlands",NA
"34","32406317","10.1080/07391102.2020.1768902","Potential anti-viral activity of approved repurposed drug against main protease of SARS-CoV-2: an <i>in silico</i> based approach.","The Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) which was first reported in Wuhan province of China, has become a deadly pandemic causing alarmingly high morbidity and mortality. In the absence of new targeted drugs and vaccines against SARS-CoV-2 at present, the choices for effective treatments are limited. Therefore, considering the exigency of the situation, we focused on identifying the available approved drugs as potential inhibitor against the promising Coronavirus drug ta","2020","05","25","J Biomol Struct Dyn","Journal of biomolecular structure &amp; dynamics","COVID-19; FDA approved drugs; Mpro; SARS-CoV-2; docking; molecular dynamics; viomycin","Mahanta","Saurov","National Institute of Electronics and Information Technology (NIELIT), Guwahati, Guwahati, Assam, India",NA
"35","32406253","10.2217/fon-2020-0381","Bacillus Calmette Gu..rin (BCG) vaccination use in the fight against COVID-19 - what's old is new again?",NA,"2020","07","06","Future Oncol","Future oncology (London, England)","BCG vaccine; COVID-19; clinical trials; coronavirus; immunotherapy; mycobacterium bovis; BCG Vaccine; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vaccination","O'Connor","Ellen","Department of Surgery, University of Melbourne, Austin Hospital, Heidelberg, Melbourne, Victoria, Australia",NA
"36","32404020","10.1177/1470320320926902","COVID-19: The race for a vaccine.",NA,"2020","06","10","J Renin Angiotensin Aldosterone Syst","Journal of the renin-angiotensin-aldosterone system : JRAAS","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Repositioning; Humans; Pandemics; Pneumonia, Viral; RNA, Viral; SARS-CoV-2; Social Control, Formal; Viral Vaccines","Lockey","Emily","Fieldfisher LLP, UK",NA
"37","32397182","10.3390/v12050518","Influenza Virus Like Particles (VLPs): Opportunities for H7N9 Vaccine Development.","In the midst of the ongoing COVID-19 coronavirus pandemic, influenza virus remains a major threat to public health due to its potential to cause epidemics and pandemics with significant human mortality. Cases of H7N9 human infections emerged in eastern China in 2013 and immediately raised pandemic concerns as historically, pandemics were caused by the introduction of new subtypes into immunologically na..ve human populations. Highly pathogenic H7N9 cases with severe disease were reported recentl","2020","05","19","Viruses","Viruses","H7N9; IAV; VLP vaccine; avian flu; pandemic influenza A; Animals; Antigens, Viral; Clinical Trials as Topic; Epitopes; Histocompatibility Antigens Class II; Humans; Influenza A Virus, H7N9 Subtype; Influenza Vaccines; Vaccines, Virus-Like Particle","Pushko","Peter","Medigen, Inc., 8420 Gas House Pike, Suite S, Frederick, MD 21701, USA",NA
"38","32396996","10.1111/all.14364","Immune response to SARS-CoV-2 and mechanisms of immunopathological changes in COVID-19.","As a zoonotic disease that has already spread globally to several million human beings and possibly to domestic and wild animals, eradication of coronavirus disease 2019 (COVID-19) appears practically impossible. There is a pressing need to improve our understanding of the immunology of this disease to contain the pandemic by developing vaccines and medicines for the prevention and treatment of patients. In this review, we aim to improve our understanding on the immune response and immunopatholo","2020","08","03","Allergy","Allergy","COVID-19; cytokine storm; immune response; immunologic tests; immunopathology; infections; pandemic; virus; Animals; Antibodies, Viral; Betacoronavirus; COVID-19; Coronavirus Infections; Cytokines; Eosinophils; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Humans; Immunity, Innate; Lymphocytes; Lymphopenia; Pandemics; Pneumonia, Viral; SARS-CoV-2; Zoonoses","Azkur","Ahmet Kursat","Department of Virology, Faculty of Veterinary Medicine, University of Kirikkale, Kirikkale, Turkey",NA
"39","32394841","10.2174/1568026620999200511092332","COVID-19: An Update on Clinical Trials.",NA,"2020","08","27","Curr Top Med Chem","Current topics in medicinal chemistry","Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Viral Vaccines","Kumar","Yogesh","Department of Chemistry Bhagini Nivedita College University of Delhi Delhi-110043, India",NA
"40","32393664","10.3899/jrheum.200493","Hydroxychloroquine in Patients with Rheumatic Disease Complicated by COVID-19: Clarifying Target Exposures and the Need for Clinical Trials.","To characterize hydroxychloroquine (HCQ) exposure in patients with rheumatic disease receiving longterm HCQ compared to target concentrations with reported antiviral activity against the coronavirus disease 2019 caused by SARS-CoV-2 (COVID-19). We evaluated total HCQ concentrations in serum and plasma from published literature values, frozen serum samples from a pediatric systemic lupus erythematosus trial, and simulated concentrations using a published pharmacokinetic model during pregnancy. Fo","2021","06","04","J Rheumatol","The Journal of rheumatology",NA,"Balevic","Stephen J","From the Department of Rheumatology and Immunology, Duke University School of Medicine, Durham, North Carolina, USA","stephen.balevic@duke.edu"
"41","32393526","10.1126/science.abc5312","A strategic approach to COVID-19 vaccine R&amp;D.",NA,"2020","06","02","Science","Science (New York, N.Y.)","Adjuvants, Immunologic; Animals; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trial Protocols as Topic; Clinical Trials as Topic; Coronavirus Infections; Disease Models, Animal; Humans; Immunogenicity, Vaccine; International Cooperation; National Institutes of Health (U.S.); Pandemics; Pneumonia, Viral; Public-Private Sector Partnerships; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus; T-Lymphocytes; United States; Vaccines, DNA; Vaccines, Synthetic; Viral Vaccines","Corey","Lawrence","Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA 98109, USA",NA
"42","32387332","10.1016/j.micinf.2020.05.001","Current development of COVID-19 diagnostics, vaccines and therapeutics.","A novel coronavirus, designated as SARS-CoV-2, first emerged in Wuhan City, Hubei Province, China, in late December 2019. The rapidly increasing number of cases has caused worldwide panic. In this review, we describe some currently applied diagnostic approaches, as well as therapeutics and vaccines, to prevent, treat and control further outbreaks of SARS-CoV-2 infection.","2020","08","14","Microbes Infect","Microbes and infection","Diagnostic approaches; SARS-CoV-2; Therapeutics; Vaccines; Animals; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines; World Health Organization","Zhang","Naru","Department of Clinical Medicine, School of Medicine, Zhejiang University City College, Hangzhou, China",NA
"43","32387041","10.1016/j.arcmed.2020.04.017","COVID-19 and Moral Imperialism in Multinational Clinical Research.","A TV debate in April 2020 between two French doctors regarding the benefits of testing a coronavirus vaccine in Africa where there are no masks or treatments available has led to international criticism. This case highlights a problematic ethical double standard in multinational clinical research: trials that would be considered unethical in high income countries (e.g., placebo-controlled where there is an existing treatment) are nonetheless justified in low-and-middle-income countries because t","2020","09","28","Arch Med Res","Archives of medical research","COVID-19; Clinical trials; Colonialism; Ethics; Low-and-middle-income countries; Research design; Africa; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Colonialism; Coronavirus Infections; Developing Countries; Ethical Relativism; Ethics, Research; France; Human Experimentation; Humans; Moral Obligations; Pandemics; Personal Protective Equipment; Pneumonia, Viral; Research Subjects; SARS-CoV-2; Viral Vaccines","Hellmann","Fernando","Department of Public Health, Federal University of Santa Catarina, Campus Universit..rio Reitor Jo..o David Ferreira Lima, Santa Catarina, Brazil. Electronic address: fernando.hellmann@ufsc","fernando.hellmann@ufsc.br"
"44","32387011","10.1016/j.vaccine.2020.04.073","Tortoises, hares, and vaccines: A cautionary note for SARS-CoV-2 vaccine development.",NA,"2020","05","22","Vaccine","Vaccine","Betacoronavirus; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Approval; Drug Development; Humans; SARS-CoV-2; Time Factors; Viral Vaccines","Poland","Gregory A","Mayo Vaccine Research Group, 611C Guggenheim Building, Mayo Clinic and Foundation, Rochester, MN 55905, USA. Electronic address: poland.gregory@mayo","poland.gregory@mayo.edu"
"45","32381692","10.1126/science.abc5798","Combination prevention for COVID-19.",NA,"2020","05","12","Science","Science (New York, N.Y.)","Antibodies, Monoclonal; Antiviral Agents; Behavior; Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Clinical Trials as Topic; Communicable Disease Control; Coronavirus Infections; HIV Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Cohen","Myron S","Myron S. Cohen is a professor in the Department of Medicine, Division of Infectious Diseases, and The Institute for Global Health and Infectious Diseases at the University of North Carolina at Chapel Hill, Chapel Hill, NC, USA. mscohen@med.unc","mscohen@med.unc.edu"
"46","32380316","10.1016/j.autrev.2020.102554","Convalescent plasma in Covid-19: Possible mechanisms of action.","Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is responsible of the coronavirus disease 2019 (COVID-19) pandemic. Therapeutic options including antimalarials, antivirals, and vaccines are under study. Meanwhile the current pandemic has called attention over old therapeutic tools to treat infectious diseases. Convalescent plasma (CP) constitutes the first option in the current situation, since it has been successfully used in other coronaviruses outbreaks. Herein, we discuss the po","2020","06","10","Autoimmun Rev","Autoimmunity reviews","ACE-2 receptor; COVID-19; Convalescent plasma; Coronavirus; Cytokines; Intravenous immunoglobulins; Neutralizing antibodies; SARS-Cov-2; Antibodies, Neutralizing; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunization, Passive; Lymphocytes; Pandemics; Pneumonia, Viral; Retrospective Studies; SARS-CoV-2","Rojas","Manuel","Center for Autoimmune Diseases Research (CREA), School of Medicine and Health Sciences, Universidad del Rosario, Bogota, Colombia",NA
"47","32378805","10.1111/1742-6723.13537","COVID-19 and toxicity from potential treatments: Panacea or poison.","Since December 2019, coronavirus disease (COVID-19) has been increasingly spreading from its origin in Wuhan, China to many countries around the world eventuating in morbidity and mortality affecting millions of people. This pandemic has proven to be a challenge given that there is no immediate cure, no vaccine is currently available and medications or treatments being used are still undergoing clinical trials. There have already been examples of self-medication and overdose. Clearly, there is a","2020","08","05","Emerg Med Australas","Emergency medicine Australasia : EMA","COVID; coronavirus; overdose; toxicology; Antiviral Agents; Azithromycin; Betacoronavirus; COVID-19; Chloroquine; Coronavirus Infections; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Treatment Outcome","Wong","Anselm","Victorian Poisons Information Centre, Austin Toxicology Unit and Emergency Department, Austin Health, Melbourne, Victoria, Australia",NA
"48","32376359","10.1016/j.micpath.2020.104236","Design of a peptide-based subunit vaccine against novel coronavirus SARS-CoV-2.","Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and has subsequently spread worldwide. In the absence of any antiviral or immunomodulatory therapies, the disease is spreading at an alarming rate. A possibility of a resurgence of COVID-19 in places where lockdowns have already worked is also developing. Thus, for controlling COVID-19, vaccines may be a better option than drugs. An mRNA-based anti-COVID-19 candidate vaccine has entered","2020","06","18","Microb Pathog","Microbial pathogenesis","Adjuvant; COVID-19; Immunogenic epitopes; Peptide vaccine; SARS-CoV-2; Subunit vaccine; Antigens, Viral; Betacoronavirus; COVID-19; Coronavirus Infections; Epitopes, B-Lymphocyte; Epitopes, T-Lymphocyte; Humans; Molecular Dynamics Simulation; Nucleocapsid Proteins; Pandemics; Pneumonia, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Vaccines, Subunit; Viral Vaccines","Kalita","Parismita","Molecular and Structural Biophysics Laboratory, Department of Biochemistry, North-Eastern Hill University, Shillong, 793022, India",NA
"49","32375002","10.1021/acs.nanolett.0c01386","Deconvoluting Lipid Nanoparticle Structure for Messenger RNA Delivery.","Lipid nanoparticle (LNP) packaged mRNA vaccines have been deployed against infectious diseases such as COVID-19, yet their structural features remain unclear. Cholesterol, a major constituent within LNPs, contributes to their morphology that influences gene delivery. Herein, we examine the structure of LNPs containing cholesterol derivatives using electron microscopy, differential scanning calorimetry, and membrane fluidity assays. LNPs formulated with C24 alkyl derivatives of cholesterol show a","2020","06","23","Nano Lett","Nano letters","cryo-TEM; gene therapy; lipid nanoparticles; mRNA delivery; Betacoronavirus; COVID-19; COVID-19 Vaccines; Cholesterol; Coronavirus Infections; Drug Carriers; Gene Transfer Techniques; HeLa Cells; Humans; Lipids; Nanoparticles; Pandemics; Phase Transition; Phytosterols; Pneumonia, Viral; RNA, Messenger; SARS-CoV-2; Transfection; Viral Vaccines","Eygeris","Yulia","Department of Pharmaceutical Sciences, College of Pharmacy, Oregon State University, Portland, Oregon 97201, United States",NA
"50","32366816","10.12659/MSM.924700","An Evidence Based Perspective on mRNA-SARS-CoV-2 Vaccine Development.","The first outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) occurred in Wuhan, Hubei Province, China, in late 2019. The subsequent COVID-19 pandemic rapidly affected the health and economy of the world. The global approach to the pandemic was to isolate populations to reduce the spread of this deadly virus while vaccines began to be developed. In March 2020, the first phase I clinical trial of a novel lipid nanoparticle (LN","2020","05","06","Med Sci Monit","Medical science monitor : international medical journal of experimental and clinical research","Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; RNA, Messenger; RNA, Viral; SARS-CoV-2; Spike Glycoprotein, Coronavirus; United States; Viral Vaccines","Wang","Fuzhou","Group of Neuropharmacology and Neurophysiology, Division of Neuroscience, The Bonoi Academy of Science and Education, Chapel Hill, NC, USA",NA
"51","32365191","10.1093/infdis/jiaa234","Balancing Expediency and Scientific Rigor in Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Development.",NA,"2020","07","07","J Infect Dis","The Journal of infectious diseases","Animals; Antibodies, Neutralizing; Antibodies, Viral; Antibody-Dependent Enhancement; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunogenicity, Vaccine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Graepel","Kevin W","Vanderbilt University School of Medicine, Nashville, Tennessee, USA",NA
"52","32363221","10.1016/j.cmrp.2020.04.001","An overview of coronaviruses including the SARS-2 coronavirus - Molecular biology, epidemiology and clinical implications.","Coronavirus infections have emerged as epidemic and pandemic threats in last two decades. After the H1N1 influenza pandemic in 2009, recently diagnosed novel betacoronavirus or severe acute respiratory syndrome coronavirus (SARS-CoV)-2 has spread across 203 countries and territories in all 5 major continents. World Health Organization (WHO) declared this as a public health emergency of international concern on January 30, 2020. Subsequently on February 11, 2020 a new name was given to this disea","2021","01","10","Curr Med Res Pract","Current medicine research and practice","Betacoronavirus; COVID-19; Coronavirus; SARS-CoV-1; SARS-CoV-2; Wuhan","Kaul","Dinesh","Pediatric Infectious Diseases, Department of Pediatrics, Sir Ganga Ram Hospital, New Delhi -110060, India",NA
"53","32359402","10.1016/S0140-6736(20)31025-4","Considering BCG vaccination to reduce the impact of COVID-19.",NA,"2020","05","19","Lancet","Lancet (London, England)","BCG Vaccine; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Immunity, Heterologous; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2","Curtis","Nigel","Department of Paediatrics, The University of Melbourne, Parkville, VIC, Australia","nigel.curtis@rch.org.au"
"54","32355008","10.1126/science.368.6490.456","COVID-19 shot protects monkeys.",NA,"2020","05","05","Science","Science (New York, N.Y.)","Animals; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Macaca mulatta; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Cohen","Jon",NA,NA
"55","32350928","10.1096/fj.202000919","Rethinking the role of hydroxychloroquine in the treatment of COVID-19.","There are currently no proven or approved treatments for coronavirus disease 2019 (COVID-19). Early anecdotal reports and limited..in vitro data led to the significant uptake of hydroxychloroquine (HCQ), and to lesser extent chloroquine (CQ), for many patients with this disease. As an increasing number of patients with COVID-19 are treated with these agents and more evidence accumulates, there continues to be no high-quality clinical data showing a clear benefit of these agents for this disease.","2020","05","06","FASEB J","FASEB journal : official publication of the Federation of American Societies for Experimental Biology","COV-SARS-2; SARS; coronavirus; immune; immunology; COVID-19; Coronavirus Infections; Datasets as Topic; Heart; Humans; Hydroxychloroquine; Immunity, Innate; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic","Meyerowitz","Eric A","Division of Infectious Diseases, Massachusetts General Hospital (MGH) and Harvard Medical School (HMS), Boston, MA, USA",NA
"56","32350686","10.1007/s12325-020-01351-9","Anti COVID-19 Drugs: Need for More Clinical Evidence and Global Action.","The World Health Organization (WHO) called the outbreak of coronavirus infectious disease-2019 (COVID-19) a &quot;Public Health Emergency of International Concern&quot; (PHEIC). According to the WHO, Centers for Disease Control and Prevention (CDC), and the US Food and Drug Administration (FDA), currently there are no medicines or vaccines that have been claimed to be useful in the prevention or treatment of COVID-19. Several existing antiviral drugs, previously developed or used as treatments f","2020","06","09","Adv Ther","Advances in therapy","Adverse effects; China; Chloroquine; Coronavirus infectious disease-2019 (COVID-19); Drugs; MERS; SARS; Therapy; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Khan","Zakir","T..bbi Farmakoloji Anabilim Dal.., T..p Fak..ltesi, ..ukurova ..niversitesi, Sar....am, Adana, Turkey. zakirkhan300@gmail","zakirkhan300@gmail.com"
"57","32350002","10.1503/cmaj.200648","Treatment of patients with nonsevere and severe coronavirus disease 2019: an evidence-based guideline.",NA,"2020","07","06","CMAJ","CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne","Adrenal Cortex Hormones; Antiviral Agents; COVID-19; Coronavirus Infections; Evidence-Based Medicine; Humans; Pandemics; Plasma; Pneumonia, Viral; Practice Guidelines as Topic; Severity of Illness Index","Ye","Zhikang","Department of Health Research Methods, Evidence and Impact Canada (Ye, Rochwerg, Guyatt, Colunga-Lozano) and of Medicine (Rochwerg), McMaster University, Hamilton, Ont.",NA
"58","32348598","10.1111/apt.15779","Review article: prevention, diagnosis and management of COVID-19 in the IBD patient.","The current COVID-19 pandemic, caused by SARS-CoV-2, has emerged as a public health emergency. All nations are seriously challenged as the virus spreads rapidly across the globe with no regard for borders. The primary management of IBD involves treating uncontrolled inflammation with most patients requiring immune-based therapies. However, these therapies may weaken the immune system and potentially place IBD patients at increased risk of infections and infectious complications including those f","2020","06","22","Aliment Pharmacol Ther","Alimentary pharmacology &amp; therapeutics","Betacoronavirus; COVID-19; Comorbidity; Coronavirus Infections; Humans; Inflammation; Inflammatory Bowel Diseases; Pandemics; Pneumonia, Viral; SARS-CoV-2","Al-Ani","Aysha H","Department of Gastroenterology, The Royal Melbourne Hospital, Melbourne, Vic., Australia",NA
"59","32346094","10.1038/s41577-020-0323-4","COVID-19 vaccine design: the Janus face of immune enhancement.",NA,"2020","06","15","Nat Rev Immunol","Nature reviews. Immunology","Animals; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Clinical Trials as Topic; Coronavirus Infections; Drug Design; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Hotez","Peter J","Texas Children's Center for Vaccine Development, Houston, TX, USA. hotez@bcm","hotez@bcm.edu"
"60","32344853","10.3390/ijerph17092986","Searching for SARS-COV-2 on Particulate Matter: A Possible Early Indicator of COVID-19 Epidemic Recurrence.","A number of nations were forced to declare a total shutdown due to COVID-19 infection, as extreme measure to cope with dramatic impact of the pandemic, with remarkable consequences both in terms of negative health outcomes and economic loses. However, in many countries a &quot;Phase-2&quot; is approaching and many activities will re-open soon, although with some differences depending on the severity of the outbreak experienced and SARS-COV-2 estimated diffusion in the general population. At the ","2020","05","06","Int J Environ Res Public Health","International journal of environmental research and public health","COVID-19; Epidemic; Indicator; Particulate Matter; RNA; Relapse; Aerosols; Betacoronavirus; COVID-19; Coronavirus; Coronavirus Infections; Disease Outbreaks; Humans; Italy; Pandemics; Particulate Matter; Pneumonia, Viral; Public Health; Quarantine; Recurrence; SARS-CoV-2","Setti","Leonardo","Department of Industrial Chemistry, University of Bologna, 40136 Bologna, Italy",NA
"61","32344202","10.1016/j.ebiom.2020.102768","Impact of immune enhancement on Covid-19 polyclonal hyperimmune globulin therapy and vaccine development.","The pandemic spread of a novel coronavirus - SARS coronavirus-2 (SARS-CoV-2) as a cause of acute respiratory illness, named Covid-19, is placing the healthcare systems of many countries under unprecedented stress. Global economies are also spiraling towards a recession in fear of this new life-threatening disease. Vaccines that prevent SARS-CoV-2 infection and therapeutics that reduces the risk of severe Covid-19 are thus urgently needed. A rapid method to derive antiviral treatment for Covid-19","2020","05","29","EBioMedicine","EBioMedicine","COVID-19; Coronavirus; Polyclonal hyperimmune globulin; SARS-CoV-2; Vaccines; Animals; Antibodies, Viral; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase I as Topic; Convalescence; Coronavirus Infections; Dendritic Cells; Global Health; Host Microbial Interactions; Humans; Immunization, Passive; Macrophages; Models, Animal; Monocytes; Pandemics; Plasma; Plasmapheresis; Pneumonia, Viral; Receptors, Fc; Translational Medical Research; Viral Vaccines; Virus Internalization","de Alwis","Ruklanthi","Program in Emerging Infectious Diseases, Duke-NUS Medical School, Singapore",NA
"62","32343658","10.3238/arztebl.2020.0213","Medication for COVID-19-an Overview of Approaches Currently Under Study.","With the worldwide spread of SARS-CoV-2 infection, it is becoming increasingly urgent to develop a vaccine to prevent COVID-19, as well as effective drugs to treat it. This article is based on a selective literature search in PubMed and ClinicalTrials.gov, followed by an assessment of the ongoing clinical trials that were revealed by the search. A number of substances have been found to prevent the reproduction of SARS-CoV-2 in vitro. These include virustatic agents that have already been approv","2020","05","01","Dtsch Arztebl Int","Deutsches Arzteblatt international","Antiviral Agents; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Stahlmann","Ralf","Institute for Clinical Pharmacology and Toxicology,Charit..-Universit..tsmedizin Berlin",NA
"63","32341719","10.1007/s13167-020-00207-0","Covid-19 pandemic by the &quot;real-time&quot; monitoring: the Tunisian case and lessons for global epidemics in the context of 3PM strategies.","Covid-19 is neither the first nor the last viral epidemic which societies around the world are, were and will be affected by. Which lessons should be taken from the current pandemic situation? The Covid-19 disease is still not well characterised, and many research teams all over the world are working on prediction of the epidemic scenario, protective measures to populations and sub-populations, therapeutic and vaccination issues, amongst others. Contextually, countries with currently low numbers","2020","09","28","EPMA J","The EPMA journal","Anti-body; Anti-gene; Bottle-neck; Comorbidities; Covid-19; Depression; Economy; Epidemics; Ethics; Home isolation; Individual outcomes; Infection; Laboratory medicine; Multi-professional expertise; Pandemic; Policymaking; Population screening; Predictive preventive personalised (3P) medicine; Psychotic attitude; Related mortality; SARS-CoV-2; Salami-tactic; Strategy; Suicide; Suppressed immune defence; Targeted protective measures; Test; Titanic; Triage; Violence; ...Real-time... monitoring","Chaari","Lotfi","University of Toulouse, IRIT - INP-ENSEEIHT (UMR 5505), 2 rue Charles Camichel, BP 7122 Toulouse Cedex 7, France",NA
"64","32341531","10.1038/s41585-020-0325-9","Could BCG be used to protect against COVID-19?",NA,"2020","06","16","Nat Rev Urol","Nature reviews. Urology","Adjuvants, Immunologic; Animals; BCG Vaccine; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Redelman-Sidi","Gil","Division of Infectious Diseases, Memorial Sloan Kettering Cancer Center, New York, NY, USA. redelmag@mskcc","redelmag@mskcc.org"
"65","32338347","10.1007/s12098-020-03292-1","COVID-19 in Children: Clinical Approach and Management.","COVID-19 pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a major public health crisis threatening humanity at this point in time. Transmission of the infection occurs by inhalation of infected droplets or direct contact with soiled surfaces and fomites. It should be suspected in all symptomatic children who have undertaken international travel in the last 14 d, all hospitalized children with severe acute respiratory illness, and asymptomatic direct and high-ris","2020","05","19","Indian J Pediatr","Indian journal of pediatrics","ARDS; Acute lung injury; Acute respiratory distress syndrome; COVID-19; Hydroxychloroquine; Lopinavir; Multiorgan dysfunction; Ritonavir; SARS-CoV-2; Severe pneumonia; Acute Lung Injury; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Testing; Child; Child, Preschool; Clinical Laboratory Techniques; Coronavirus Infections; Disease Outbreaks; Humans; Hydroxychloroquine; Infant; Lopinavir; Palliative Care; Pandemics; Pneumonia, Viral; Protease Inhibitors; Respiratory Distress Syndrome; Reverse Transcriptase Polymerase Chain Reaction; Ritonavir; SARS-CoV-2; Severe Acute Respiratory Syndrome","Sankar","Jhuma","Department of Pediatrics, All India Institute of Medical Sciences, New Delhi, 110029, India",NA
"66","32331807","10.1016/j.vaccine.2020.04.039","Extraordinary diseases require extraordinary solutions.",NA,"2021","04","13","Vaccine","Vaccine","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans","Plotkin","Stanley A","Pediatrics, University of Pennsylvania, PA, USA. Electronic address: stanley.plotkin@vaxconsult","stanley.plotkin@vaxconsult.com"
"67","32330122","10.1172/JCI139562","Panic prescribing has become omnipresent during the COVID-19 pandemic.",NA,"2020","06","11","J Clin Invest","The Journal of clinical investigation","COVID-19; Betacoronavirus; COVID-19; Clinical Trials as Topic; Compassionate Use Trials; Coronavirus Infections; Drug Repositioning; Drugs, Investigational; Ebola Vaccines; Hemorrhagic Fever, Ebola; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Caplan","Arthur L","Division of Medical Ethics, New York University Grossman School of Medicine, New York, New York, USA",NA
"68","32327600","10.1126/science.abc1731","Against pandemic research exceptionalism.",NA,"2020","05","12","Science","Science (New York, N.Y.)","COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; Viral Vaccines","London","Alex John","Center for Ethics and Policy, Carnegie Mellon University, Pittsburgh, PA, USA",NA
"69","32327575","10.1126/science.368.6489.351","NIH organizes hunt for drugs.",NA,"2020","05","14","Science","Science (New York, N.Y.)","Antiviral Agents; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; National Institutes of Health (U.S.); Pandemics; Pneumonia, Viral; United States; Viral Vaccines","Kaiser","Jocelyn",NA,NA
"70","32325038","10.1016/S1473-3099(20)30160-2","Safety and immunogenicity of a candidate Middle East respiratory syndrome coronavirus viral-vectored vaccine: a dose-escalation, open-label, non-randomised, uncontrolled, phase 1 trial.","Cases of Middle East respiratory syndrome coronavirus (MERS-CoV) infection continue to rise in the Arabian Peninsula 7 years after it was first described in Saudi Arabia. MERS-CoV poses a significant risk to public health security because of an absence of currently available effective countermeasures. We aimed to assess the safety and immunogenicity of the candidate simian adenovirus-vectored vaccine expressing the full-length spike surface glycoprotein, ChAdOx1 MERS, in humans. This dose-escala","2020","09","09","Lancet Infect Dis","The Lancet. Infectious diseases","Adult; Antibodies, Neutralizing; Antibodies, Viral; Coronavirus Infections; Dose-Response Relationship, Immunologic; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunogenicity, Vaccine; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; United Kingdom; Viral Vaccines; Young Adult","Folegatti","Pedro M","The Jenner Institute, Nuffield Department of Medicine, University of Oxford, Oxford, UK",NA
"71","32325037","10.1016/S1473-3099(20)30248-6","Safety and immunogenicity of a modified vaccinia virus Ankara vector vaccine candidate for Middle East respiratory syndrome: an open-label, phase 1 trial.","The Middle East respiratory syndrome coronavirus (MERS-CoV) causes a respiratory disease with a case fatality rate of up to 35%. Given its potential to cause a public health emergency and the absence of efficacious drugs or vaccines, MERS is one of the WHO priority diseases warranting urgent research and development of countermeasures. We aimed to assess safety and tolerability of an anti-MERS-CoV modified vaccinia virus Ankara (MVA)-based vaccine candidate that expresses the MERS-CoV spike glyc","2020","09","09","Lancet Infect Dis","The Lancet. Infectious diseases","Adult; Antibodies, Viral; Coronavirus Infections; Dose-Response Relationship, Immunologic; Enzyme-Linked Immunosorbent Assay; Female; Genetic Vectors; Germany; Humans; Immunization, Secondary; Immunogenicity, Vaccine; Male; Middle Aged; Middle East Respiratory Syndrome Coronavirus; Neutralization Tests; Vaccinia virus; Viral Vaccines; Young Adult","Koch","Till","First Department of Medicine, Division of Infectious Diseases, University Medical Center Hamburg-Eppendorf, Hamburg, Germany",NA
"72","32320592","10.1056/NEJMe2012889","Audio Interview: Approaches to Covid-19 Vaccines and Antivirals.",NA,"2020","04","27","N Engl J Med","The New England journal of medicine","Adaptive Immunity; Anti-Inflammatory Agents; Antibodies, Monoclonal; Antibodies, Neutralizing; Antiviral Agents; Betacoronavirus; COVID-19; Coronavirus Infections; Drug Development; Humans; Immunization, Passive; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; SARS-CoV-2; Time Factors; Viral Vaccines","Rubin","Eric J",NA,NA
"73","32320059","10.1002/jmv.25920","Potential of live pathogen vaccines for defeating the COVID-19 pandemic: History and mechanism.","The whole world has entered a terrible crisis with a huge and increasing number of human deaths and economic losses in fighting the pandemic of COVID-19 caused by the novel coronavirus termed SARS-CoV-2. The live pathogen vaccine (LPV) strategy, which originated in ancient China for fighting smallpox, has been applied successfully by US military recruits for decades to control acute respiratory diseases caused by types 4 and 7 adenoviruses. This strategy has also been widely employed in veterina","2020","12","16","J Med Virol","Journal of medical virology","antiviral; coronavirus; pandemic; safety; strategy; vaccine; Animals; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Humans; Pandemics; Safety; Vaccines, Attenuated","Chen","Ji-Wang","Department of Medicine, University of Illinois at Chicago, Chicago, Illinois",NA
"74","32318706","10.1093/jpids/piaa045","Multicenter Initial Guidance on Use of Antivirals for Children With Coronavirus Disease 2019/Severe Acute Respiratory Syndrome Coronavirus 2.","Although coronavirus disease 2019 (COVID-19) is mild in nearly all children, a small proportion of pediatric patients develop severe or critical illness. Guidance is therefore needed regarding use of agents with potential activity against severe acute respiratory syndrome coronavirus 2 in pediatrics. A panel of pediatric infectious diseases physicians and pharmacists from 18 geographically diverse North American institutions was convened. Through a series of teleconferences and web-based surveys","2021","02","12","J Pediatric Infect Dis Soc","Journal of the Pediatric Infectious Diseases Society","COVID-19; SARS-CoV-2; antiviral; guidance; pediatric; Antiviral Agents; COVID-19; Child; Humans; Risk Assessment; Severity of Illness Index","Chiotos","Kathleen","Department of Anesthesia and Critical Care Medicine, Division of Critical Care Medicine, Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, USA",NA
"75","32317431","10.4103/ijo.IJO_639_20","Therapeutic opportunities to manage COVID-19/SARS-CoV-2 infection: Present and future.","A severe form of respiratory disease - COVID-19, caused by SARS-CoV-2 infection, has evolved into a pandemic resulting in significant morbidity and mortality. The unabated spread of the disease is due to lack of vaccine and effective therapeutic agents against this novel virus. Hence, the situation demands an immediate need to explore all the plausible therapeutic and prophylactic strategies that can be made available to stem the spread of the disease. Towards this effort, the current review out","2020","04","27","Indian J Ophthalmol","Indian journal of ophthalmology","COVID-19; SARS-CoV-2; prophylaxis; therapy; Animals; Betacoronavirus; COVID-19; Coronavirus Infections; Humans; Immunity, Active; Morbidity; Pandemics; Pneumonia, Viral; SARS-CoV-2; Virus Replication","Shetty","Rohit","Narayana Nethralaya, Bangalore, Karnataka, India",NA
"76","32313823","10.1007/s13337-020-00579-x","One month of the novel coronavirus 2019 outbreak: Is it still a threat?","The novel coronavirus 2019 disease (COVID-19) is now in an outbreak not only in China but also around the world, suspected to be originated from a wet market in Wuhan, Hubei province, China. The flare-up of COVID-19, it has already been infected 78,811 people with 2462 fatalities in 1..month window. The most alarming issue is the virus can transmit from host to host and still asymptomatic. Currently, 24 counties with 505 confirmed cases have been reported. Presently, there is no specific treatme","2021","04","28","Virusdisease","Virusdisease","COVID-19; Novel coronavirus 2019; SARS-CoV-2; Wuhan","Chowdhury","Apu","School of Medicine, Xi'an Jiaotong University, Xi'an, 710061 China",NA
"77","32311668","10.1016/j.intimp.2020.106519","SARS-Cov-2 infection: Response of human immune system and possible implications for the rapid test and treatment.","The new coronavirus outbreak is an ongoing pandemic that is caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The new coronavirus SARS-Cov-2 belongs to the subfamily of ..-coronaviruses and shares 79.5% of the genetic sequence of SARS-CoV, the causative agent of the epidemic that started in 2002 and ended in 2004. Considering the clinical impact of the new outbreak, it is highly important to study the potential responses of the human immune system during the SARS-CoV-2 infe","2020","06","18","Int Immunopharmacol","International immunopharmacology","Human immune system; Outbreak; Pharmacological treatments; Rapid test; SARS-Cov-2 infection; Anti-Inflammatory Agents; Antibodies, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Inflammation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Sensitivity and Specificity; Serologic Tests; Time Factors; Viral Vaccines","di Mauro","Gabriella","Department of Experimental Medicine, University of Campania &quot","gabriella.dimauro@unicampania.it"
"78","32306836","10.1080/07391102.2020.1758788","Novel 2019 coronavirus structure, mechanism of action, antiviral drug promises and rule out against its treatment.","In the past two decades, the world has faced several infectious disease outbreaks. Ebola, Influenza A (H1N1), SARS, MERS, and Zika virus have had a massive global impact in terms of economic disruption, the strain on local and global public health. Most recently, the global outbreak of novel coronavirus 2019 (SARS-CoV-2) that causes COVID-19 is a newly discovered virus from the coronavirus family in Wuhan city, China, known to be a great threat to the public health systems. As of 15 April 2020, ","2021","05","19","J Biomol Struct Dyn","Journal of biomolecular structure &amp; dynamics","ACE2 receptor; COVID-19; Coronavirus; antiviral drugs; computational simulation; coronavirus Spike","Boopathi","Subramanian","Centro de Bioinform..tica y Simulaci..n Molecular (CBSM), Universidad de Talca, Talca, Chile",NA
"79","32305089","10.1016/S0140-6736(20)30796-0","Sarah Gilbert: carving a path towards a COVID-19 vaccine.",NA,"2020","04","28","Lancet","Lancet (London, England)","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; DNA, Recombinant; Drug Development; History, 20th Century; History, 21st Century; Humans; Pandemics; Pneumonia, Viral; Research Design; Research Support as Topic; SARS-CoV-2; United Kingdom; Vaccines, Synthetic; Viral Vaccines","Lane","Richard",NA,NA
"80","32304435","10.1097/COC.0000000000000712","The Impact of the COVID-19 Pandemic on Cancer Patients.","In December 2019, a novel coronavirus called severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak of coronavirus disease 2019 (COVID-19). Severe complications have been reported to occur in 33% of patients with COVID-19 and include acute respiratory distress syndrome, acute renal failure, acute respiratory injury, septic shock, and severe pneumonia. Currently, there is no specific treatment or approved vaccine against COVID-19 and many clinical trials are currently inv","2020","06","04","Am J Clin Oncol","American journal of clinical oncology","Betacoronavirus; COVID-19; Coronavirus Infections; Disease Management; Health Personnel; Humans; Incidence; Neoplasms; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; SARS-CoV-2","Al-Quteimat","Osama M","Pharmacy Services Department, Cleveland Clinic Abu Dhabi, Abu Dhabi, UAE",NA
"81","32303704","10.1038/s41565-020-0680-y","The race against COVID-19.",NA,"2020","04","23","Nat Nanotechnol","Nature nanotechnology","Adenosine Monophosphate; Alanine; Antibodies, Viral; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Clinical Trials as Topic; Coronavirus Infections; Humans; Hydroxychloroquine; Nucleic Acid Amplification Techniques; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines",NA,NA,NA,NA
"82","32302280","10.5811/westjem.2020.3.47328","Brief Summary of Potential SARS-CoV-2 Prophylactic and Treatment Drugs in the Emergency Department.","As of March 30<sup>th</sup>, 2020 there were 161,807 total cases and 2,953 total deaths of SARS-CoV-2 in the United States, with the number of cases expected to rise. Other than supportive care, there are no SARS-CoV-2 specific treatments available for patients discharged from the emergency department (ED) or those admitted to the hospital. In addition, there are no vaccines available to protect our at-risk healthcare workers. The National Institutes of Health is conducting a Phase 1 clinical tr","2020","05","21","West J Emerg Med","The western journal of emergency medicine","Betacoronavirus; COVID-19; Coronavirus; Coronavirus Infections; Emergency Service, Hospital; Humans; Immunization, Passive; Pandemics; Pneumonia, Viral; Pre-Exposure Prophylaxis; SARS-CoV-2; United States","Brown","Cortlyn","University of California San Francisco, Department of Emergency Medicine, San Francisco, California",NA
"83","32300051","10.1136/jitc-2020-000878","Insights from immuno-oncology: the Society for Immunotherapy of Cancer Statement on access to IL-6-targeting therapies for COVID-19.",NA,"2020","04","21","J Immunother Cancer","Journal for immunotherapy of cancer","immunomodulation; inflammation mediators; Betacoronavirus; COVID-19; Coronavirus Infections; Drug Approval; Humans; Immunologic Factors; Immunotherapy; Inflammation; Interleukin-6; Neoplasms; Pandemics; Pneumonia, Viral; Receptors, Interleukin-6; SARS-CoV-2","Ascierto","Paolo Antonio","Istituto Nazionale Tumori IRCCS Fondazione Pascale, Napoli, Italy",NA
"84","32297723","10.4081/monaldi.2020.1292","COVID-2019: update on epidemiology, disease spread and management.","With each passing day, more cases of Coronavirus disease (COVID-2019) are being detected and unfortunately the fear of novel corona virus 2019 (2019-nCoV) becoming a pandemic disease has come true. Constant efforts at individual, national, and international level are being made in order to understand the genomics, hosts, modes of transmission and epidemiological link of nCoV-2019. As of now, whole genome sequence of the newly discovered coronavirus has already been decoded. Genomic characterizat","2020","04","20","Monaldi Arch Chest Dis","Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace","Adenosine Monophosphate; Alanine; Angiotensin-Converting Enzyme 2; Antiviral Agents; Basic Reproduction Number; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Peptidyl-Dipeptidase A; Pneumonia, Viral; Quarantine; Receptors, Virus; SARS-CoV-2","Sahu","Kamal Kant","Department of Internal medicine, Saint Vincent Hospital, Worcester, Massachusetts, United States of America, 01608. Kamalkant.Sahu@stvincenthospital","Kamalkant.Sahu@stvincenthospital.com"
"85","32295694","10.1691/ph.2020.0444","COVID-19 vaccination clinical trials should consider multiple doses of BCG.",NA,"2020","04","20","Pharmazie","Die Pharmazie","BCG Vaccine; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Vaccination; Viral Vaccines","Ayoub","B M","The Center for Drug Research and Development (CDRD), Pharmaceutical Chemistry Department, Faculty of Pharmacy, The British University in Egypt, El-Sherouk City, Cairo, Egypt","bassam.ayoub@bue.edu.eg"
"86","32294922","10.3390/ijerph17082655","Benefits of Exercise on Influenza or Pneumonia in Older Adults: A Systematic Review.","A coronavirus pandemic has recently become one of the greatest threats the world is facing. Older adults are under a high risk of infection because of weaker immune systems. Therefore, the purpose of this review is to summarize the recent scientific evidence that outlines the effects of exercise on influenza or pneumonia in older adults. An electronic literature search was conducted using the WEB OF SCIENCE, SCIENCEDIRECT and GOOGLE SCHOLAR databases using the following keywords, &quot;Exercise,","2020","07","23","Int J Environ Res Public Health","International journal of environmental research and public health","exercise; influenza; older adults; pneumonia; Aged; Betacoronavirus; COVID-19; Coronavirus Infections; Cross-Sectional Studies; Exercise Therapy; Female; Humans; Influenza, Human; Male; Observational Studies as Topic; Pandemics; Pneumonia, Viral; Randomized Controlled Trials as Topic; Risk Assessment; SARS-CoV-2","Song","Yang","Faculty of Sports Science, Ningbo University, Ningbo 315211, China",NA
"87","32292527","10.1007/s12561-020-09277-0","On a Statistical Transmission Model in Analysis of the Early Phase of COVID-19 Outbreak.","Since December 2019, a disease caused by a novel strain of coronavirus (COVID-19) had infected many people and the cumulative confirmed cases have reached almost 180,000 as of 17, March 2020. The COVID-19 outbreak was believed to have emerged from a seafood market in Wuhan, a metropolis city of more than 11 million population in Hubei province, China. We introduced a statistical disease transmission model using case symptom onset data to estimate the transmissibility of the early-phase outbreak ","2020","09","28","Stat Biosci","Statistics in biosciences","Basic reproduction number; COVID-19; Emerging outbreak; Transmission model","Zhu","Yifan","Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, 1100 Fairview Ave. N., Seattle, WA 98109 USA",NA
"88","32292113","10.1089/scd.2020.0071","Stem Cell-Based Therapy for Coronavirus Disease 2019.","The novel coronavirus disease 2019 (COVID-19) has grown to be a global public-health emergency since patients were first detected in Wuhan, China, in December 2019. As of April 9, 2020, the novel coronavirus (named as SARS-CoV-2 by the International Committee on Taxonomy of Viruses on February 11) has infected 83,251 and 1,484,811 patients in China and the world, respectively. However, we have neither confirmed effective antiviral medications nor vaccines available to deal with this emergency. I","2020","06","15","Stem Cells Dev","Stem cells and development","COVID-19; clinical trial; transplantation; Betacoronavirus; COVID-19; Cell Differentiation; Cell- and Tissue-Based Therapy; Coronavirus Infections; Dendritic Cells; Humans; Mesenchymal Stem Cell Transplantation; Mesenchymal Stem Cells; Pandemics; Pneumonia, Viral; SARS-CoV-2","Zhao","Robert Chunhua","Department of Cell Biology, School of Life Sciences, Shanghai University, Shanghai, PR China",NA
"89","32291999","10.22092/ari.2019.124720.1286","Immunogenicity and Efficacy of Live Infectious Bronchitis 793/B.08IR Vaccine in SPF Chickens.","Infectious bronchitis virus (IBV) has a variety of serotypes with relatively limited cross-protection leading the disease to be a major problem in the poultry industry. The IBV 793/B strain has identified to circulate in Iran; therefore, the development of a specific vaccine to protect against the virulent virus has received attention. In this regard, the live IB 793/B vaccine (793/B.08IR) was developed in the Razi Vaccine and Serum Research Institute. In this study, the immunogenicity of 793/B.","2020","08","31","Arch Razi Inst","Archives of Razi Institute","793/B strain; Efficacy; IBV vaccine; Immunogenicity; SPF; Animals; Chickens; Coronavirus Infections; Immunogenicity, Vaccine; Infectious bronchitis virus; Poultry Diseases; Specific Pathogen-Free Organisms; Vaccines, Attenuated","Masoudi","S","Department of production of Infectious Bronchitis and Encephalomyelytis Vaccines, Razi Vaccine and Serum Research Institute, Agricultural Research, Education and Extension Organization (AREEO), Karaj, Iran",NA
"90","32290293","10.3390/ijms21072657","A Review of SARS-CoV-2 and the Ongoing Clinical Trials.","The sudden outbreak of 2019 novel coronavirus (2019-nCoV, later named SARS-CoV-2) in Wuhan, China, which rapidly grew into a global pandemic, marked the third introduction of a virulent coronavirus into the human society, affecting not only the healthcare system, but also the global economy. Although our understanding of coronaviruses has undergone a huge leap after two precedents, the effective approaches to treatment and epidemiological control are still lacking. In this article, we present a ","2020","04","16","Int J Mol Sci","International journal of molecular sciences","ACE2; COVID-19; SARS-CoV-2; clinical trials; immunotherapy; pneumonia; replicase; vaccine; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Genome, Viral; Humans; Immunization, Passive; Immunologic Factors; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Tu","Yung-Fang","Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan",NA
"91","32282894","10.7326/M20-1301","Diagnostic Testing for Severe Acute Respiratory Syndrome-Related Coronavirus 2: A Narrative Review.","Diagnostic testing to identify persons infected with severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) infection is central to control the global pandemic of COVID-19 that began in late 2019. In a few countries, the use of diagnostic testing on a massive scale has been a cornerstone of successful containment strategies. In contrast, the United States, hampered by limited testing capacity, has prioritized testing for specific groups of persons. Real-time reverse transcriptase p","2020","06","08","Ann Intern Med","Annals of internal medicine","Antibodies; Antigens; COVID-19; Cells; Infectious disease immunology; Nucleic acids; Prevention, policy, and public health; Pulmonary diseases; Research laboratories; Upper respiratory tract infections; Betacoronavirus; Biomarkers; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Point-of-Care Testing; Radiography, Thoracic; Real-Time Polymerase Chain Reaction; SARS-CoV-2; Serologic Tests; Specimen Handling","Cheng","Matthew P","McGill University Health Centre and McGill Interdisciplinary Initiative in Infection and Immunity, Montreal, Quebec, Canada (M.P",NA
"92","32282303","10.2174/1568026620999200413145654","Coronavirus Disease (COVID-19) Pandemic: A Race Against Time.",NA,"2020","08","05","Curr Top Med Chem","Current topics in medicinal chemistry","Adenosine Monophosphate; Alanine; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Hand Hygiene; Humans; International Cooperation; Masks; Pandemics; Patient Education as Topic; Pneumonia, Viral; Quarantine; SARS-CoV-2; Viral Vaccines","Banerjee","Amit K","Biology Division, Indian Institute of Chemical Technology Hyderabad-500007, Telangana, India",NA
"93","32282038","10.1093/cid/ciaa433","The VACCINES Act: Deciphering Vaccine Hesitancy in the Time of COVID-19.","Since the COVID-19 pandemic first hit Wuhan, China, in December 2019, scientists have been racing to develop and test novel vaccines to protect against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The speed of scientific discovery related to COVID-19 is unprecedented. With several vaccine candidates already being tested in clinical trials, we pose the question: what will the vaccine hesitant do in the face of this pandemic?","2020","08","05","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; antivax; immunization; vaccine hesitancy; Betacoronavirus; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Immunization Programs; Legislation, Drug; Pandemics; Patient Education as Topic; Pneumonia, Viral; SARS-CoV-2; United States; Vaccination Refusal; Viral Vaccines","McAteer","John","Department of Pediatrics, Emory University School of Medicine, Atlanta, Georgia, USA",NA
"94","32273621","10.1038/d41586-020-01063-8","If a coronavirus vaccine arrives, can the world make enough?",NA,"2020","04","30","Nature","Nature","SARS-CoV-2; Vaccines; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Coronavirus Infections; Developed Countries; Drug Industry; Health Care Rationing; Health Resources; Hoarding; Humans; Immunization, Secondary; International Cooperation; Investments; Pandemics; Pneumonia, Viral; Socioeconomic Factors; Strategic Stockpile; Time Factors; Tobacco; Vaccines, Subunit; Vaccines, Synthetic; Viral Vaccines; World Health Organization","Khamsi","Roxanne",NA,NA
"95","32273591","10.1038/d41573-020-00073-5","The COVID-19 vaccine development landscape.",NA,"2020","05","06","Nat Rev Drug Discov","Nature reviews. Drug discovery","Aged; Betacoronavirus; COVID-19; COVID-19 Vaccines; Child; Clinical Trials, Phase I as Topic; Coronavirus Infections; Drug Development; Drug Industry; Female; Genetic Vectors; Humans; Internationality; Pandemics; Pneumonia, Viral; Pregnancy; SARS-CoV-2; Time Factors; Vaccines, Attenuated; Vaccines, Inactivated; Vaccines, Subunit; Vaccines, Synthetic; Viral Vaccines","Thanh Le","Tung",NA,NA
"96","32259480","10.1016/j.immuni.2020.03.007","SARS-CoV-2 Vaccines: Status Report.","SARS-CoV-2, the causal agent of COVID-19, first emerged in late 2019 in China. It has since infected more than 870,000 individuals and caused more than 43,000 deaths globally. Here, we discuss therapeutic and prophylactic interventions for SARS-CoV-2 with a focus on vaccine development and its challenges. Vaccines are being rapidly developed but will likely come too late to affect the first wave of a potential pandemic. Nevertheless, critical lessons can be learned for the development of vaccine","2020","04","24","Immunity","Immunity","Animals; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus; Coronavirus Infections; Disease Models, Animal; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Time Factors; Viral Vaccines","Amanat","Fatima","Graduate School of Biomedical Sciences, Icahn School of Medicine at Mount Sinai, New York, NY, USA",NA
"98","32247193","10.1016/j.jns.2020.116803","Guidance for the management of myasthenia gravis (MG) and Lambert-Eaton myasthenic syndrome (LEMS) during the COVID-19 pandemic.",NA,"2020","04","28","J Neurol Sci","Journal of the neurological sciences","Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Disease Management; Disease Susceptibility; Humans; Immunoglobulins, Intravenous; Immunologic Factors; Immunosuppressive Agents; Immunotherapy; Lambert-Eaton Myasthenic Syndrome; Myasthenia Gravis; Pandemics; Plasma Exchange; Pneumonia, Viral; SARS-CoV-2; Vaccines","Jacob","Saiju","Department of Neurology, Institute of Immunology and Immunotherapy, University Hospitals, Birmingham B15 2TH, United Kingdom. Electronic address: saiju.jacob@uhb.nhs","saiju.jacob@uhb.nhs.uk"
"99","32243270","10.1097/JCMA.0000000000000318","Potential therapeutic agents against COVID-19: What we know so far.","The emerging outbreak of coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 continues to spread all over the world. Agents or vaccines of proven efficacy to treat or prevent human coronavirus infection are in urgent need and are being investigated vigorously worldwide. This review summarizes the current evidence of potential therapeutic agents, such as lopinavir/ritonavir, remdesivir, favipiravir, chloroquine, hydroxychloroquine, interferon, ribavir","2020","06","16","J Chin Med Assoc","Journal of the Chinese Medical Association : JCMA","Adenosine Monophosphate; Alanine; Betacoronavirus; COVID-19; Clinical Trials as Topic; Coronavirus Infections; Drug Combinations; Humans; Hydroxychloroquine; Interferon-alpha; Lopinavir; Pandemics; Pneumonia, Viral; Ritonavir; SARS-CoV-2","Lu","Chih-Chia","Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan, ROC",NA
"100","32241928","10.1126/science.368.6486.14","Vaccine designers take first shots at COVID-19.",NA,"2020","04","07","Science","Science (New York, N.Y.)","Antibodies, Viral; Betacoronavirus; Biomedical Research; Biotechnology; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Immunologic Memory; Lung; Pandemics; Pneumonia, Viral; RNA, Messenger; SARS-CoV-2; Spike Glycoprotein, Coronavirus; Viral Vaccines","Cohen","Jon","With reporting by Kai Kupferschmidt",NA
"101","32234468","10.1016/j.ijantimicag.2020.105955","The epidemiology, diagnosis and treatment of COVID-19.","In December 2019, the outbreak of the novel coronavirus disease (COVID-19) in China spread worldwide, becoming an emergency of major international concern. SARS-CoV-2 infection causes clusters of severe respiratory illness similar to severe acute respiratory syndrome coronavirus. Human-to-human transmission via droplets, contaminated hands or surfaces has been described, with incubation times of 2-14 days. Early diagnosis, quarantine, and supportive treatments are essential to cure patients. Thi","2020","05","28","Int J Antimicrob Agents","International journal of antimicrobial agents","COVID-19; Clinical trials; Diagnosis; Isolation; Pandemic; Remdesivir; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Testing; Clinical Laboratory Techniques; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2","Zhai","Pan","Department of Neurology, Hubei Provincial Hospital of Traditional Chinese Medicine, Wuhan, 430073, Hubei, China",NA
"102","32234130","10.3760/cma.j.cn112150-20200317-00366","[Progress and challenge of vaccine development against 2019-novel coronavirus (2019-nCoV)].","The outbreak of 2019-novel coronavirus (2019-nCoV) infection poses a serious threat to global public health. Vaccination is an effective way to prevent the epidemic of the virus. 2019-nCoV along with severe acute respiratory syndrome coronavirus (SARS-CoV) and Middle East respiratory syndrome coronavirus (MERS-CoV) belong to the same ..-genus of coronavirus family. Basing on the previous experience and the technical platform of developing SARS-CoV and MERS-CoV vaccines, scientists from all over ","2020","08","28","Zhonghua Yu Fang Yi Xue Za Zhi","Zhonghua yu fang yi xue za zhi [Chinese journal of preventive medicine]","2019-nCoV; Animal models; Vaccine; Biomedical Research; COVID-19; COVID-19 Vaccines; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Viral Vaccines","Shi","Y","Institute of Biopharmaceutical Research, West China Hospital, Sichuan University, Chengdu 610041, China",NA
"103","32233561","10.3934/mbe.2020147","Effects of media reporting on mitigating spread of COVID-19 in the early phase of the outbreak.","The 2019 novel coronavirus disease (COVID-19) is running rampantly in China and is swiftly spreading to other countries in the world, which causes a great concern on the global public health. The absence of specific therapeutic treatment or effective vaccine against COVID-19 call for other avenues of the prevention and control measures. Media reporting is thought to be effective to curb the spreading of an emergency disease in the early stage. Cross-correlation analysis based on our collected da","2020","04","09","Math Biosci Eng","Mathematical biosciences and engineering : MBE"," COVID-19 ;  basic reproduction number ;  mathematical model ;  media reporting ;  sensitivity analysis ; Basic Reproduction Number; Betacoronavirus; COVID-19; China; Communicable Disease Control; Communication; Computer Simulation; Coronavirus Infections; Humans; Mass Media; Models, Theoretical; Pandemics; Pneumonia, Viral; Public Health; SARS-CoV-2","Zhou","Wei Ke","College of Mathematics and Information Science, Shaanxi Normal University, Xi'an 710062, China",NA
"104","32232474","10.1093/infdis/jiaa152","Human Challenge Studies to Accelerate Coronavirus Vaccine Licensure.","Controlled human challenge trials of SARS-CoV-2 vaccine candidates could accelerate the testing and potential rollout of efficacious vaccines. By replacing conventional phase 3 testing of vaccine candidates, such trials may subtract many months from the licensure process, making efficacious vaccines available more quickly. Obviously, challenging volunteers with this live virus risks inducing severe disease and possibly even death. However, we argue that such studies, by accelerating vaccine eval","2020","05","19","J Infect Dis","The Journal of infectious diseases"," coronavirus; ethics; human challenge studies; randomized controlled trials; risk-taking; vaccines; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Licensure; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Eyal","Nir","Center for Population-Level Bioethics, Rutgers University, New Brunswick, New Jersey, USA",NA
"105","32232214","","Potential Treatments for COVID-19; a Narrative Literature Review.","SARS-CoV-2 is a newly emerging human infectious coronavirus that causes COVID-19, which has been recognized as a pandemic by the World Health Organization (WHO) on March 11<sup>th</sup>. There is still no vaccine or definitive treatment for this virus because its pathogenesis and proliferation pathways are still unknown. Therefore, in this article, new potential COVID-19 therapies are briefly reviewed.","2020","09","28","Arch Acad Emerg Med","Archives of academic emergency medicine","COVID-19; Case reports; Clinical trial; Coronavirus; Drug therapy; Review","Rismanbaf","Ali","Department of Clinical Pharmacy and Pharmacy Practice, School of Pharmacy and Pharmaceutical Sciences, Isfahan University of Medical Sciences, Isfahan, Iran",NA
"106","32231348","10.4081/monaldi.2020.1289","Emerging prophylaxis strategies against COVID-19.","The Novel corona virus 2019 which started as an outbreak in China in December 2019 has rapidly spread all over the world, such that on 11th March 2020 WHO declared this disease as pandemic. The emergency that the world faces today demands that we develop urgent and effective measures to protect people at high risk of transmission. WHO has accelerated research in diagnostics, vaccines and therapeutics for this novel coronavirus.","2020","04","02","Monaldi Arch Chest Dis","Monaldi archives for chest disease = Archivio Monaldi per le malattie del torace","Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; Chemoprevention; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; Humans; Hydroxychloroquine; Pandemics; Pneumonia, Viral; SARS-CoV-2; Viral Vaccines","Agrawal","Sumita","Pulmonary Medicine and Critical Care, Medipulse Hospitals, Jodhpur. drsumi84@gmail","drsumi84@gmail.com"
"107","32229574","10.1073/pnas.2005456117","News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine.",NA,"2020","04","20","Proc Natl Acad Sci U S A","Proceedings of the National Academy of Sciences of the United States of America","Animals; Antibody-Dependent Enhancement; Antigens, Viral; Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Humans; Inflammation; Pandemics; Pneumonia, Viral; SARS-CoV-2; Severe Acute Respiratory Syndrome; T-Lymphocytes; Viral Vaccines","Peeples","Lynne",NA,NA
"108","32227757","10.1056/NEJMp2005630","Developing Covid-19 Vaccines at Pandemic Speed.",NA,"2020","05","26","N Engl J Med","The New England journal of medicine","Betacoronavirus; COVID-19; COVID-19 Vaccines; Clinical Trials as Topic; Coronavirus Infections; Drug Development; Humans; Pandemics; Pneumonia, Viral; SARS-CoV-2; Time Factors; Vaccines, Synthetic; Viral Vaccines","Lurie","Nicole","From the Coalition for Epidemic Preparedness Innovations, Oslo",NA
"109","32226695","10.7759/cureus.7343","Acetazolamide, Nifedipine and Phosphodiesterase Inhibitors: Rationale for Their Utilization as Adjunctive Countermeasures in the Treatment of Coronavirus Disease 2019 (COVID-19).","Effective treatments for Coronavirus Disease 2019 (COVID-19)..outbreak are urgently needed. While anti-viral approaches and..vaccines are being considered..immediate countermeasures are unavailable. The aim of this article is to outline a perspective on the pathophysiology of COVID-19 in the context of the currently available clinical data published in the literature. This article appreciates clinical data..published on COVID-19 in the context of another respiratory illness - high altitude pulmo","2020","09","28","Cureus","Cureus","acetazolamide; coronavirus; covid-19; covid-2019; ground glass opacities; high altitude pulmonary edema; hypoxia; novel coronavirus; respiratory care; wuhan coronavirus","Solaimanzadeh","Isaac","Internal Medicine, Interfaith Medical Center, Brooklyn, USA",NA
"110","32226288","10.7150/ijbs.45538","Traditional Chinese Medicine in the Treatment of Patients Infected with 2019-New Coronavirus (SARS-CoV-2): A Review and Perspective.","Currently, Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2, formerly known as 2019-nCoV, the causative pathogen of Coronavirus Disease 2019 (COVID-19)) has rapidly spread across China and around the world, causing an outbreak of acute infectious pneumonia. No specific anti-virus drugs or vaccines are available for the treatment of this sudden and lethal disease. The supportive care and non-specific treatment to ameliorate the symptoms of the patient are the only options currently. At","2020","04","03","Int J Biol Sci","International journal of biological sciences","SARS-CoV-2; Traditional Chinese Medicine (TCM); coronavirus pneumonia; Betacoronavirus; COVID-19; China; Clinical Trials as Topic; Coronavirus Infections; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Pandemics; Phytotherapy; Pneumonia, Viral; SARS-CoV-2","Yang","Yang","State Key Laboratory of Quality Research in Chinese Medicine, Institute of Chinese Medical Sciences, University of Macau, Macau SAR 999078, China",NA
"111","32221519","10.1093/cid/ciaa344","Antibody Responses to SARS-CoV-2 in Patients With Novel Coronavirus Disease 2019.","The novel coronavirus SARS-CoV-2 is a newly emerging virus. The antibody response in infected patients remains largely unknown, and the clinical value of antibody testing has not been fully demonstrated. 173 patients with SARS-CoV-2 infection were enrolled. Their serial plasma samples (n...=...535) collected during hospitalization were tested for total antibodies (Ab), IgM, and IgG against SARS-CoV-2. The dynamics of antibodies with disease progress were analyzed. Among 173 patients, the serocon","2020","12","14","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; SARS-CoV-2; antibody; Adult; Aged; Antibodies, Viral; Antibody Formation; COVID-19; Enzyme-Linked Immunosorbent Assay; Female; Humans; Immunoglobulin G; Immunoglobulin M; Male; Middle Aged; Pandemics; SARS-CoV-2; Serologic Tests","Zhao","Juanjuan","Institute of Hepatology, National Clinical Research Center for Infectious Disease, Shenzhen Third People's Hospital, Shenzhen, China",NA
"112","32215622","10.1093/cid/ciaa325","Simulation of the Clinical and Pathological Manifestations of Coronavirus Disease 2019 (COVID-19) in a Golden Syrian Hamster Model: Implications for Disease Pathogenesis and Transmissibility.","A physiological small-animal model that resembles COVID-19 with low mortality is lacking. Molecular docking on the binding between angiotensin-converting enzyme 2 (ACE2) of common laboratory mammals and the receptor-binding domain of the surface spike protein of SARS-CoV-2 suggested that the golden Syrian hamster is an option. Virus challenge, contact transmission, and passive immunoprophylaxis studies were performed. Serial organ tissues and blood were harvested for histopathology, viral load a","2020","12","14","Clin Infect Dis","Clinical infectious diseases : an official publication of the Infectious Diseases Society of America","COVID-19; SARS-CoV-2; animal; coronavirus; transmission; Animals; Antibodies, Neutralizing; Antibodies, Viral; COVID-19; Cricetinae; Disease Models, Animal; Lung; Molecular Docking Simulation; SARS-CoV-2; Viral Load","Chan","Jasper Fuk-Woo","State Key Laboratory of Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, China",NA
"113","32214240","10.1038/d41586-020-00889-6","Coronavirus shuts down trials of drugs for multiple other diseases.",NA,"2020","06","15","Nature","Nature","Cancer; Infection; Medical research; Public health; Animals; Biomedical Research; COVID-19; COVID-19 Vaccines; Child; Clinical Trials as Topic; Coronavirus Infections; Drug Approval; Drug Industry; Humans; Male; National Institutes of Health (U.S.); Osteochondrodysplasias; Pandemics; Pneumonia, Viral; Stress, Psychological; Uncertainty; United States; Viral Vaccines","Ledford","Heidi",NA,NA
"114","32212920","10.1146/annurev-virology-013120-013123","Ethics of Conducting Clinical Research in an Outbreak Setting.","The conduct of clinical trials during the West Africa Ebola outbreak in 2014 highlighted many ethical challenges. How these challenges were addressed, what clinical studies were conducted during that outbreak, and the lessons learned for dealing with future outbreaks were the subject of a National Academy of Medicine committee report titled Integrating Clinical Research into Epidemic Response: The Ebola Experience. This report suggested improvements for research during subsequent emerging","2020","10","14","Annu Rev Virol","Annual review of virology","Ebola; clinical research; coronavirus; epidemic; ethics; outbreak; pregnant women; Adult; Africa, Western; Antiviral Agents; Biomedical Research; Child; Clinical Trials as Topic; Disease Outbreaks; Ebola Vaccines; Ebolavirus; Female; Hemorrhagic Fever, Ebola; Humans; International Cooperation; Male; Patient Selection; Pregnancy; Survival Analysis","Edwards","Kathryn M","Division of Pediatric Infectious Diseases, Vanderbilt University School of Medicine, Nashville, Tennessee 37232, USA","Kathryn.edwards@vumc.org"
"115","32205459","10.1126/science.abb8492","Underpromise, overdeliver.",NA,"2020","04","01","Science","Science (New York, N.Y.)","Betacoronavirus; Biomedical Research; COVID-19; COVID-19 Testing; COVID-19 Vaccines; Clinical Laboratory Techniques; Clinical Trials as Topic; Coronavirus Infections; Humans; Pandemics; Pneumonia, Viral; Polymerase Chain Reaction; SARS-CoV-2; Viral Vaccines","Thorp","H Holden","H. Holden Thorp Editor-in-Chief, Science journals. hthorp@aaas","hthorp@aaas.org"
"116","32203367","10.1038/d41586-020-00798-8","Coronavirus vaccines: five key questions as trials begin.",NA,"2020","06","01","Nature","Nature","Infection; Virology; Animals; Biomedical Research; COVID-19; COVID-19 Vaccines; Clinical Trials, Phase I as Topic; Coronavirus Infections; Disease Models, Animal; Guinea Pigs; Humans; Immunologic Memory; Macaca mulatta; Mice; Pandemics; Pneumonia, Viral; Risk Assessment; Spike Glycoprotein, Coronavirus; T-Lymphocytes; Time Factors; Viral Vaccines","Callaway","Ewen",NA,NA
"117","32197097","10.1016/S1473-3099(20)30123-7","Disease X: accelerating the development of medical countermeasures for the next pandemic.","WHO has listed several priority diseases with epidemic potential for which there are no, or insufficient, medical countermeasures. In response, the Bill &amp; Melinda Gates Foundation (with support from PricewaterhouseCoopers) coordinated subject matter experts to create a preparedness plan for Disease X. Disease X is caused by Pathogen X, an infectious agent that is not currently known to cause human disease, but an aetiologic agent of a future outbreak with epidemic or pandemic potential. We h","2020","08","07","Lancet Infect Dis","The Lancet. Infectious diseases","Animals; COVID-19; Coronavirus Infections; Disease Outbreaks; Global Health; Humans; Medical Countermeasures; Pandemics; Pneumonia, Viral; Vaccines","Simpson","Shmona","The Bill &amp","shmona.simpson@gatesfoundation.org"
"118","32179860","10.1038/d41586-020-00751-9","Don't rush to deploy COVID-19 vaccines and drugs without sufficient safety guarantees.",NA,"2020","03","20","Nature","Nature","Medical research; Vaccines; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Drug Evaluation, Preclinical; Humans; Immunity; Models, Animal; Patient Safety; Pneumonia, Viral; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Viral Vaccines","Jiang","Shibo",NA,NA
"119","32146554","10.1007/s10729-020-09504-6","Containing 2019-nCoV (Wuhan) coronavirus.","The novel coronavirus 2019-nCoV first appeared in December 2019 in Wuhan, China. While most of the initial cases were linked to the Huanan Seafood Wholesale Market, person-to-person transmission has been verified. Given that a vaccine cannot be developed and deployed for at least a year, preventing further transmission relies upon standard principles of containment, two of which are the isolation of known cases and the quarantine of persons believed at high risk of exposure. This note presents p","2020","08","24","Health Care Manag Sci","Health care management science","Containment; Coronavirus; Isolation; Probability modeling; Quarantine; Betacoronavirus; COVID-19; China; Communicable Disease Control; Contact Tracing; Coronavirus Infections; Disease Outbreaks; Humans; Models, Theoretical; Pandemics; Pneumonia, Viral; Probability; Quarantine; SARS-CoV-2","Kaplan","Edward H","William N. and Marie A. Beach Professor of Operations Research, Professor of Public Health, Professor of Engineering, Yale School of Management, 165 Whitney Avenue, New Haven, 06511, CT, USA. edward.kaplan@yale","edward.kaplan@yale.edu"
"120","32134116","10.1002/jmv.25748","Unique epidemiological and clinical features of the emerging 2019 novel coronavirus pneumonia (COVID-19) implicate special control measures.","By 27 February 2020, the outbreak of coronavirus disease 2019 (COVID-19) caused 82...623 confirmed cases and 2858 deaths globally, more than severe acute respiratory syndrome (SARS) (8273 cases, 775 deaths) and Middle East respiratory syndrome (MERS) (1139 cases, 431 deaths) caused in 2003 and 2013, respectively. COVID-19 has spread to 46 countries internationally. Total fatality rate of COVID-19 is estimated at 3.46% by far based on published data from the Chinese Center for Disease Control and","2020","06","30","J Med Virol","Journal of medical virology","COVID-19; diagnosis and interventions; features; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Communicable Disease Control; Coronavirus Infections; Humans; Immunization, Passive; Lymphopenia; Middle East Respiratory Syndrome Coronavirus; Pandemics; Pneumonia, Viral; Prevalence; SARS Virus; SARS-CoV-2; Severe Acute Respiratory Syndrome; Survival Analysis; Thrombocytopenia; Viral Vaccines","Wang","Yixuan","Laboratory of Human Virology and Oncology, Shantou University Medical College, Shantou, Guangdong, China",NA
"121","32110875","10.3390/jcm9030623","Potential Rapid Diagnostics, Vaccine and Therapeutics for 2019 Novel Coronavirus (2019-nCoV): A Systematic Review.","Rapid diagnostics, vaccines and therapeutics are important interventions for the management of the 2019 novel coronavirus (2019-nCoV) outbreak. It is timely to systematically review the potential of these interventions, including those for Middle East respiratory syndrome-Coronavirus (MERS-CoV) and severe acute respiratory syndrome (SARS)-CoV, to guide policymakers globally on their prioritization of resources for research and development. A systematic search was carried out in three major elect","2020","09","28","J Clin Med","Journal of clinical medicine","MERS-CoV; SARS-CoV; diagnostics; global health; novel coronavirus; outbreak; treatments; vaccine","Pang","Junxiong","Saw Swee Hock School of Public Health, National University of Singapore and National University Health System, Singapore 117549, Singapore",NA
"122","32108352","10.1002/jmv.25733","Clinical trial analysis of 2019-nCoV therapy registered in China.","So far, there is a lack of effective drugs for the new coronavirus pneumonia. With more and more patients diagnosed, China has carried out more than 100 clinical studies of new coronavirus infection, including antiviral drugs, antimalarial drugs, glucocorticoids, plasma therapy, virus vaccine, and other Western drugs, while Chinese medicine research accounted for half of the studies. Most of the trials were initiated by investigators and the study period would last for 1 to 11 months. The primar","2020","06","30","J Med Virol","Journal of medical virology","China; clinical trial; new coronavirus pneumonia; new drugs; Adenosine Monophosphate; Alanine; Amides; Antiviral Agents; Betacoronavirus; COVID-19; China; Chloroquine; Clinical Trials as Topic; Coronavirus Infections; Disease Management; Disease Outbreaks; Drugs, Chinese Herbal; Humans; Medicine, Chinese Traditional; Pandemics; Pneumonia, Viral; Practice Guidelines as Topic; Pyrazines; SARS-CoV-2","Zhang","Qi","Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Gastrointestinal Oncology, Peking University Cancer Hospital and Institute, Beijing, China",NA
"123","32048890","10.1080/21645515.2019.1705691","Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan.","The study was aimed at comparative evaluation of seasonal influenza vaccine RIBSP versus commercial vaccine VAXIGRIP.. for immunogenicity and safety in the course of clinical trial phase II on healthy subjects up to 60 years. The trial involved 150 subjects in randomized 2:1 groups that received either RIBSP vaccine or comparator vaccine VAXIGRIP... One dose (0.5 ml) of either vaccine contained 15 ..g of hemagglutinin of each influenza virus strain recommended by WHO for the Northern hemisphere ","2021","04","28","Hum Vaccin Immunother","Human vaccines &amp; immunotherapeutics","Humoral immunity; Influenza virus; Vaccines/vaccines strains","Sarsenbayeva","Gulbanu","Research Institute for Biological Safety Problems , Gvardeysk, Kazakhstan",NA
"124","32001631","10.1126/science.367.6477.492","New coronavirus threat galvanizes scientists.",NA,"2020","04","08","Science","Science (New York, N.Y.)","Animals; Antiviral Agents; Betacoronavirus; COVID-19; COVID-19 Vaccines; China; Clinical Trials as Topic; Coronavirus Infections; Disease Outbreaks; Genome, Viral; Global Health; Humans; SARS-CoV-2; Viral Vaccines","Cohen","Jon",NA,NA
"125","31899942","10.1080/03079457.2019.1710462","Effect of IBV D1466 on egg production and egg quality and the effect of heterologous priming to increase the efficacy of an inactivated IBV vaccine.","To protect layers, breeders and grandparents against damage by infectious bronchitis virus infections during the laying period, vaccination using live priming followed by a boost with inactivated IB vaccine is commonly used. For many IB variants, homologous live vaccines are not available for priming. Very little is known about the efficacy of priming with heterologous live IB vaccines (or combination of live IB vaccines) to induce broad IB protection in long-living chickens. In this study, the ","2020","11","24","Avian Pathol","Avian pathology : journal of the W.V.P.A","Heterologous priming; IBV D1466; inactivated vaccine; layers; protection; Animals; Chickens; Coronavirus Infections; Eggs; Female; Infectious bronchitis virus; Oviposition; Poultry Diseases; Tissue Culture Techniques; Trachea; Vaccines, Inactivated; Viral Vaccines","Sjaak de Wit","J J","Royal GD, Deventer, Netherlands",NA
"126","32288873","10.1016/j.livsci.2017.08.011","Immune response of mature cows subjected to annual booster vaccination against neonatal calf diarrhoea with two different commercial vaccines: A non-inferiority study.","Neonatal calf diarrhoea can have important economic consequences. Scour vaccines are available against some of the most frequent pathogens responsible for this disease: Bovine Rotavirus (BoRV), Bovine Coronavirus (BoCV) and E. coli K99. In this multi-centre, randomised, blinded study, adult cows vaccinated with a trivalent vaccine marketed for years (Rotavec... Corona, MSD Animal Health - RC) prior to last parturition were revaccinated 12-15 months later, prior to the upcoming parturition","2020","09","28","Livest Sci","Livestock science","Colostrum; Coronavirus; K99; Neonatal calf diarrhoea; Rotavirus; Vaccine","Durel","Luc","Virbac S.A., 13..me rue L.I.D., F-06511 Carros Cedex, France",NA
